

Invited review

Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of 5 series



Amy Christine Brown

Department of Complementary and Alternative Medicine, John A. Burns School of Medicine, 651 Ilalo Street, MEB 223, University of Hawaii at Manoa, Honolulu, HI, 96813, USA

ARTICLE INFO

Article history:

Received 8 February 2016
 Received in revised form
 30 June 2016
 Accepted 1 July 2016
 Available online 8 July 2016

Keywords:

Hepatotoxicity
 Toxicity
 Liver
 Herb
 Dietary supplement
 Hepatitis

ABSTRACT

Background: No online current list of potentially life-threatening, hepatotoxic herbs and dietary supplements based on PubMed case reports exists in a summarized tabular form.

Methods: Documented case reports of herbs or dietary supplements (DS; includes herbs) appearing to contribute to liver injury were used to create an online “DS Toxic Table” of potentially hepatotoxic herbs and dietary supplements (PubMed, 1966 to June, 2016, and cross-referencing). The spectrum of DS induced liver injuries (DSILI) included elevated liver enzymes, hepatitis, steatosis, cholestasis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, veno-occlusive disease, acute liver failure requiring a liver transplant, and death.

Results: Over the past 50 years, approximately 21 herbs (minus germander and usnic acid that are no longer sold) and 12 dietary supplements (minus the nine no longer sold and vitamin A & niacin due to excess intake) posed a possible risk for liver injury in certain individuals. The herbs with the most number of reported publications (but not cases studies) in descending order, were germander, black cohosh, kava extract, and green tea extract.

Conclusion: These online DS Toxic Tables will contribute to continued Phase IV post marketing surveillance to detect possible liver toxicity cases and serve to forewarn consumers, clinicians, and corporations.

© 2017 Elsevier Ltd. All rights reserved.

Contents

1. Introduction	473
2. Defining hepatotoxicity	473
2.1. DILI versus DSLI	473
2.2. Hepatotoxicity symptoms	473
2.3. Unpredictable versus predictable hepatotoxicity	473
2.4. Time to onset	474
3. Risk factors for liver injury	474
3.1. Age	474
3.2. Gender	474
3.3. Dose	474
3.4. Malnutrition	474
3.5. Alcoholism	474
3.6. Genetics	474
3.7. Race	475
3.8. Concomitant drugs (or DS)	475
3.9. Underlying disease	475
4. Causality scoring systems	475

E-mail address: amybrown@hawaii.edu.

<http://dx.doi.org/10.1016/j.fct.2016.07.001>

0278-6915/© 2017 Elsevier Ltd. All rights reserved.

4.1. Causality assessment considerations	476
5. Treatment of DILI	476
6. Prevalence of DILI and DSILI in North America & Europe	476
6.1. Retrospective and prospective prevalence studies	476
6.2. DILI versus DSILI prevalence	476
6.3. Prevalence of acute liver failure leading to liver transplant or death	477
7. DILI and DSILI prevalence in Asia, Africa, South America, and other areas	477
8. Creating DS Toxic Tables	478
9. Methods: literature search	478
10. Results: DS-Related liver injuries	478
11. Discussion	486
11.1. Herb-related liver injuries	486
11.2. Dietary supplement-related liver injuries	487
11.2.1. Weight-loss products	487
11.2.2. Withdrawal of hepatotoxic products	492
12. A balanced perspective	492
13. Current regulations	494
14. Limitations	494
15. Additional case reports	495
16. DS Toxic tables for proactive protection	495
17. Bullet summary	495
17.1. Dietary supplements	495
17.2. Balanced perspective	496
Conflict of interest/Caveat	496
Transparency document	496
References	496

1. Introduction

This is the second of five review articles investigating dietary supplements (DS; includes herbs): Article one covers DS definitions, usage, efficacy and safety, and an overview of DS regulation in the United States (Brown, 2017a); and articles two through five cover case reports in tabular form related to liver toxicity, kidney toxicity, cardiotoxicity, and cancer published in the medical literature (Brown, 2017b,c, 2017a,b). Interest in complementary and alternative medicine (CAM), also known as functional, integrative, traditional, or holistic medicine, continues to grow, but “natural” is not always safe. Although the majority of botanical products appear inherently safe (Marcus and Grollman, 2002), and some have demonstrated efficacy, this review focuses on the potentially life-threatening dietary supplements that increase liver injury risk as detected through PubMed case reports. Case reports do not always demonstrate causation or association, but reoccurrences raise concerns (Haaz et al., 2006).

In this review, the characteristics and prevalence of liver injuries are defined, the literature search methods employed are described, and a summary table of the results along with a brief discussion of selected DS are presented.

2. Defining hepatotoxicity

2.1. DILI versus DSILI

The equivalent of drug-induced liver injury (DILI), which is caused by drugs, is herb- and DS-induced liver injury (DSILI; previously described as HILI, which only covers herbs and thus excludes many products in the broader DS category). The vast majority of pharmaceuticals have beneficial effects, but adverse events (AE) or serious adverse events (SAE) related to either drugs or DS do occur, though they are rare events. Because the liver is

responsible for eliminating toxins from the body, it is at risk for drug- or DS-related liver injuries caused directly by these substances or indirectly through their metabolites (Au et al., 2011). Subsequent injury can occur through cell stress, mitochondrial inhibition, and/or immune reactions. Table 1 lists the selected possible liver injuries associated with either drugs or DS in ascending order of severity (Stedman, 2002).

2.2. Hepatotoxicity symptoms

Consumers need to recognize liver injury symptoms so that the harmful substance can be immediately removed/discontinued to improve chances of recovery. Unfortunately, the typical symptoms—including fatigue, nausea, vomiting, loss of appetite, itching, abdominal pain or swelling, and dark urine color—are vague and mimic many other conditions. A physician should be immediately consulted if these symptoms appear, and especially if jaundice (yellowing of eye whites and inner palms) appears (note, however, that jaundice does not always develop) (Zheng and Navarro, 2015).

2.3. Unpredictable versus predictable hepatotoxicity

Hepatotoxicity, like all toxicities, is either unpredictable (idiosyncratic, meaning peculiar to the individual) or predictable (classical or intrinsic) (Brent, 1999; Gunawan and Kaplowitz, 2004). Most reactions to drugs or DS are idiosyncratic because they cause toxicity in only a small percentage of the population, may not be dose dependent, may not be reproducible in animal models, and may result from an immune-mediated reaction (indicated by fever, rash, and eosinophilia) (Brent, 1999; Gunawan and Kaplowitz, 2004).

Table 1
Selected liver injuries briefly defined.

Type of liver injury	Definition
Elevated liver enzymes	Two- or three-fold + or greater increase: ^a
Elevated bilirubin	Alkaline transferase (ALT); Alkaline phosphatase (ALP)
	Two-fold or greater increase in: Bilirubin in the presence of increased ALT and ALP
Jaundice	Yellowish pigmentation of the skin and whites of eyes along with possible darker urine (due to high bilirubin levels)
Hepatitis (acute or chronic)	Inflammation of the liver
Cholestasis	Impaired bile flow
Steatosis (Fatty liver disease)	Excessive accumulation of fat in the liver cells
Fibrosis	Excessive connective tissues builds up in the liver
Veno-occlusive disease	Connective tissue and collagen block hepatic veins
Cirrhosis	Liver tissue becomes scarred and loses function
Necrosis	Death of liver tissue
Acute liver failure	Rapid (1–12 weeks) liver dysfunction in a patient without prior known liver disease
Chronic liver disease or failure	Liver disease for over 6 months resulting in gradual loss of liver function to the point of failure
Hepatic encephalopathy	Liver failure contributing to confusion, altered consciousness level, and coma
Liver transplant	Diseased liver (or portion) is replaced with a healthy liver (or portion). Follows acute liver failure or end-stage liver disease.
Death	18,146 due to alcoholic liver disease ^b 18,281 not due to alcohol (chronic liver disease and cirrhosis)

FDA-b, 2009. See American College of Gastroenterology for the latest diagnostic recommendations.

^a Teschke et al., 2013a.

^b <http://www.cdc.gov/nchs/fastats/liver-disease.htm> (2013).

2.4. Time to onset

Idiosyncratic reactions may occur within days or within up to one year, but usually by 6 months (Chalasani et al., 2014). Latency can be very short for certain drugs, averaging 2.5 days for the quinolones from ciprofloxacin, moxifloxacin, levofloxacin, and gatifloxacin. Serious outcomes from these short latencies can include liver transplant and/or death (Leise et al., 2014).

Classic liver injuries are predictable, are dose dependent, are reproducible in animal models, and may occur within hours to a few days post-exposure (Kaplowitz, 2004).

3. Risk factors for liver injury

As discussed below, factors that increase the risk for DILI or DSILI include older age, female gender, higher dose, malnutrition, alcoholism, genetics, race, concomitant drugs, and underlying disease (Andrade et al., 2008; Chalasani, 2010). To predict DILI risk for specific drugs in development, the DILIsym[®] software program (www.dilisyms.com) and the Mechanism Based Integrated System of using *in vitro* assays (www.pip-dili.eu) can be used.

3.1. Age

Liver injury risk increases as people age (Andrade et al., 2008).

3.2. Gender

Females have a higher risk of developing DILI, but this might be due to the types of drugs they more frequently consume, such as antidepressants. Autoimmune hepatitis triggered by drugs is almost exclusively diagnosed in women (Andrade et al., 2008).

3.3. Dose

A high daily dose (over 50–100 mg/day) of a medication may result in a higher DILI risk (Chen et al., 2013; Yu et al., 2014). Drugs withdrawn from the market in the United States are often administered in doses exceeding 50 mg (Chalasani et al., 2014). It is not

surprising that some of the DS-related liver toxicities are also associated with excessive doses. For example, seeds of *Psoralea corylifolia* are routinely used in China for osteoporosis, but 10 times the usual dose resulted in a case of acute hepatitis (Nam et al., 2005).

3.4. Malnutrition

Protein-calorie malnutrition, restricted feeding, fasting, and starvation can increase the toxicity of some drugs. Fasting is actually recommended before scheduling certain chemotherapy drugs (Campbell and Hayes, 1974).

3.5. Alcoholism

A liver compromised by alcohol abuse is more prone to DILI (Andrade et al., 2008).

3.6. Genetics

Patients respond differently to medications, and considerable evidence suggests that idiosyncratic DILI susceptibility is genetically determined (Urban et al., 2014). The International Serious Adverse Event Consortium (iSAEC), a nonprofit research organization, was founded in 2007 to identify DNA differences related to drug-related serious adverse events (www.saeconsortium.org).

Cytochrome P450 (CYP3A4) is the most abundant CYP enzyme in the liver, metabolizing approximately 50% of current drugs (Zhou et al., 2007). CYP gene defects are responsible for some types of drug-induced hepatitis (Kawaguchi et al., 2004), and Zhou et al. (2007) lists a number of drugs and chemicals from DS that are CYP3A4 inhibitors. Clinical consequences range from lack of therapeutic efficacy to severe toxicity, and in extreme cases, death (Zhou et al., 2007).

The mechanism may involve genetic influences on the P450 liver enzymes that metabolize drugs. Having particular alleles that either inhibit or promote certain liver enzymes, especially in the presence of competing drugs or DS, may predispose an individual to liver injury (Stedman, 2002). For example, a genetic basis for

flucloxacillin DILI is well established, with an 80-fold increase in risk if the (HLA)-B*5701 allele is present.

In terms of DS, some individuals may have a genetic predisposition to kava toxicity, as Russmann found that two patients were poor-metabolizer phenotypes of cytochrome P4502D6 (Russmann et al., 2001). Kavalactones inhibit CYP enzymes (CYP1A2, CYP2D6) or cyclooxygenases (COX-1, COX-2), or deplete hepatic glutathione. Eight percent of European people have a CYP2D6 deficiency that may place them at a greater risk for kava toxicity than Pacific Islanders, of whom only 1% are CYP2D6 deficient (Chitturi and Farrell, 2008).

Another DS extract, epigallocatechin gallate (EGCG), the suspected problematic agent in green tea was found to be tolerated by most genetically heterogeneous mice (84%), but a small fraction (16%) experienced severe hepatotoxicity (10–87% liver necrosis). A similar pattern was observed in humans (Church et al., 2015). It has been suggested that this animal model can be used to detect rare liver injuries that may occur in consumer populations ingesting concentrated herbal products. The species used to test for liver toxicity may be important, as rats are reportedly not very sensitive to hepatotoxicity, whereas both mice and hamsters are very sensitive (Davis et al., 1974).

3.7. Race

Asian race has been reported as an independent risk factor for DILI, especially for reducing the time period to liver transplant or death (Fontana et al., 2014). Aldehyde dehydrogenase enzyme levels in Asians are known to affect their ability to metabolize alcohol (Thomasson et al., 1993). Lee et al. (2013) found that related allele frequencies among Koreans were similar to those of Japanese and Chinese of Han descent, but differed from European-Americans and African-Americans. Up to 14% of Japanese carry the CYP2C19 poor-metabolizer phenotype.

It has been suggested that the low incidence of liver injuries related to a particular weight-loss supplement (containing N-nitrosfenfluramine) may have contributed to DILI in a few select individuals (Chitturi and Farrell, 2008). Approximately 4% of the United States population is Asian, but 71% (5/7) of the people experiencing acute hepatitis with LipoKinetix use in one case series report were Japanese nationals (Favreau et al., 2002). Three Taiwanese sisters consuming a usnic-containing fat-burner experienced dark urine, jaundice, and hepatitis, respectively (Hsu et al., 2005).

Another example is the leading drug responsible for idiosyncratic DILI is the antibiotic amoxicillin-clavulanate (Lucena et al., 2011). This drug causes more liver injuries in people bearing certain alleles, especially among the Spanish population (Stephens et al., 2013).

3.8. Concomitant drugs (or DS)

The competition for liver enzymes suggests that certain drug–drug, drug–DS, or DS–DS interactions can be predisposing factors for liver injuries. The possible competition between co-administered substances for liver enzymes would explain certain case reports where liver injury followed the addition of a drug or DS to a previously unproblematic drug or DS regimen (Chalasanani et al., 2014 ACG). When the same enzymes in the liver must metabolize two substances, the rate of metabolism of one or both compounds may be compromised (Zhou et al., 2007). Alcohol interferes with drug metabolism and is often contraindicated with certain drugs.

3.9. Underlying disease

Co-morbidity may also increase the risk of liver injuries, and mortality is significantly higher in individuals with pre-existing liver disease (Chalasanani et al., 2015). This is concerning since approximately 18% of chronic liver disease patients surveyed were taking herbal supplements (Ferrucci et al., 2010). Perhaps the safest approach for people on medications with pre-existing medical conditions is to avoid any DS, except perhaps a standard multivitamin/mineral supplement. Likewise, anyone undergoing a transplant or skin grafts may best avoid DS entirely, especially St. John's wort, which has been reported to reduce cyclosporine levels, resulting in the rejection of transplanted organs or graft loss (Zhou et al., 2007). Another herb, milk thistle, often used to promote liver health, reduces the mean trough level of the HIV drug, indinavir, by 25% (Zhou et al., 2007).

4. Causality scoring systems

DILI or DSILI diagnosis is primarily a process of elimination based on mathematical probability (Garcia-Cortez, 2011). Expert opinion remains the gold standard, with a physician reviewing the patient's history, blood test results, hepatobiliary imaging, and, possibly, liver biopsy results (Chalasanani et al., 2014). After a liver injury is clearly diagnosed, the cause is pinpointed through any of several methods divided into three categories: (1) expert opinion, (2) probabilistic approaches, and/or (3) scoring scales (liver-specific or general) (Garcia-Cortez, 2011).

The most commonly used liver-specific scale was developed by the Council for International Organizations of Medical Sciences (CIOMS), also known as the Rouseel Uclaf Causality Assessment Method (RUCAM) (García-Cortés et al., 2011). A checklist is reviewed by a clinician, who assigns points to each variable. The total score is evaluated using a probability scale: ≤ 0 , excluded; 1–2, unlikely; 3–5, possible; 6–8, probable; ≥ 9 , highly probable/definite. The MV Scale or Clinical Diagnostic Scale (CDS) is a shortened version of the CIOMS scale (Maria and Victorino, 1997) (Teschke et al., 2013a). On the other hand, the more recently developed Digestive Disease Week–Japan (DDW-J) scale (Takikawa et al., 2003) derived from the CIOMS scale was reported by Garcia-Cortez (2011) to be superior to that of the CIOMS. Non-liver-specific scales or those not validated for hepatotoxicity include the Naranjo Scale used in clinical trials (Naranjo et al., 1981a), the WHO-UMC causality assessment (WHO), and the ad hoc approach (Kaplowitz, 2001). The strengths and weaknesses of these different causality assessment tools were reviewed by García-Cortés et al. (2011).

Some researchers have expressed the “urgent need for a universally accepted stepwise causality assessment” scoring scale that should then be further evaluated in the field (Teschke et al., 2008). They stressed the importance of replacing the currently approved, but different, approaches of hospitals, physicians, health care agencies, manufacturers, and expert groups, which use their own method(s) that may or may not be free of conflicts of interest. Legitimate concern has been expressed regarding the US Pharmacopeia's (USP's) use of the Naranjo and not the CIOMS scale or its validated update to conduct DS liver-specific causality assessments (Teschke and Schulze, 2012a).

These scoring systems are important because drug or DS-related liver failure rarely occurs, and if a cluster of failures occur, it is imperative to quickly track down the cause and prevent further cases. A cluster of cases often points to one common denominator that can be mathematically determined as either a random or statistically significant event. Another strong support

for causation is similar symptoms with re-exposure to a substance—i.e., symptoms stabilize following withdrawal, reappear with reintroduction, and disappear again following a second withdrawal. These rechallenge tests unintentionally created by the patient are the gold standard in diagnosing hepatotoxicity (Teschke et al., 2008).

4.1. Causality assessment considerations

Approximately 47% of suspected DILI cases are in fact not caused by drugs, and researchers have stated the same is true for DSILI cases. “In 573 cases of initially assumed HILI (DSILI), 48.5% showed alternative causes. They called for thorough clinical evaluations and appropriate causality assessments in future cases of suspected DSILI” (Teschke et al., 2013c). These alternative causes included co-medication (DILI and other HILI) (43.9%), biliary and pancreatic diseases (11.5%), autoimmune diseases (10.4%), pre-existing liver diseases (including cirrhosis; 9.7%), viral hepatitis (9.7%), nonalcoholic and alcoholic liver diseases (5.4%), and infectious diseases involving the liver (4.7%). Establishing liver injury causality is necessary for accurate prevalence determinations or comparisons.

5. Treatment of DILI

DILI treatment consists of immediately withdrawing the responsible medication; many patients start to improve within hours or days (Chalasanani et al., 2014). In one study, most of the 70 patients, with elevated liver enzymes and a normal liver biopsy, recovered (Strasser et al., 2015). However, approximately 14% go on to develop chronic liver disease (Chalasanani et al., 2014). DILI from antidepressants may be irreversible (Voican et al., 2014). A minority of patients experience acute liver failure and may die or require emergency transplantation (Fontana et al., 2010).

Sometimes the liver has an autoimmune reaction to certain drugs or metabolites that bind to a liver protein (such as cytochrome p450), generating an antigen, or result in dead cells; both can trigger the immune system (Yuan and Kaplowitz, 2013). Particular attention should be given to patients who present with positive autoantibodies or a history of weight gain or alcohol consumption. (Chalasanani et al., 2014).

6. Prevalence of DILI and DSILI in North America & Europe

DILI cases, whether they are caused by drugs or DS, are not tracked through annual surveillance. DILI is rare for most drugs, occurring in approximately one per 10,000–1,000,000 persons exposed (Fontana et al., 2010). However, epidemiologic data suggest that the rate might be as high as 20 DILI cases per 100,000 people exposed in Western countries (Leise et al., 2014). The prevalence of DILI is largely unknown, as hospitals and liver centers do not appear to have similar causality determinations or report to one agency.

6.1. Retrospective and prospective prevalence studies

DILI epidemiology research results are influenced by study design, study definitions, inclusion or exclusion of acetaminophen, geography, culture, genetics, inclusion or exclusion of complementary medicine (definitions vary), and whether the researchers report conflicts of interest (Björnsson et al., 2013; Leise et al., 2014). Few prospective population-based studies have attempted to decipher the relatively low frequency of liver injuries (Fontana

et al., 2010). Several relevant findings are briefly summarized here even though data from registries cannot be considered population based (Raschi and De Ponti, 2015).

Among 83,265 in-patient admissions at the Mayo Clinic in Scottsdale, Arizona over 7 years (1998–2006), only 0.048% (N = 40) were due to DILI. That is equivalent to 5.7 cases per year. Seventy percent of these (27/40) were due to acetaminophen (APAP), and 33% (13/40) to non-APAP drugs, primarily antibiotics (Carey et al., 2008). No cases of liver injury caused by herb use were reported at this location during these 7 years.

Although DILI is a relatively rare occurrence (Chalasanani et al., 2008), the FDA cites it as the number one reason for withdrawing drugs from the marketplace over the past 50 years (FDA-b, 2009). Only about 1% of all marketed drugs were withdrawn or restricted (Wysowski and Swartz, 2005), so those causing hepatotoxicity would represent only a fraction of 1%. More than 800 drugs have been implicated in DILI (Kaplowitz, 2004). Excluding APAP, the drugs most commonly involved are antibiotics and antiepileptics, which are responsible for over 60% of the DILI (Chalasanani and Björnsson, 2010). Drugs are the number one cause among the approximately 2000 annual cases of acute liver failure (ALF) in the United States (FDA-b, 2009). However, about half of these DILI were due to APAP (Lee, 2012), and almost half of the APAP-related cases were suicide attempts with excessive doses (FDA, 2007). Fontana (2008) estimated that 500 deaths due to APAP occur in the U.S. annually. In 2015, the other major causes of acute liver failure, in descending order, were undetermined (12%), non-APAP drugs (11%), autoimmune conditions (7%), hepatitis B (7%), and hepatitis A (2%).

Acute liver failure is the diagnosis in approximately 11% of the DILI in the United States. One of the most serious consequences of liver injuries, liver transplant, is even less common (Leise et al., 2014).

6.2. DILI versus DSILI prevalence

The true prevalence of DSILI is unknown (Stickel and Shouval, 2015). However, DS contribute significantly less than pharmaceuticals to DSILI. When considering all liver injuries and not just acute liver failure, Bunchorntavakul et al. estimated that, “based on available data of DILI cohorts from the US and Europe, herbal products are implicated as a cause of hepatotoxicity in 2–11% of patients” (Bunchorntavakul and Reddy, 2013).

In 2003, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the Drug-Induced Liver Injury Network (DILIN) consisting of 8 academic medical centers and a data coordinating center (www.dilin.org) (Fontana et al., 2014). A DILIN retrospective evaluation of United States liver injuries enrolled the first 300 patients diagnosed with drug-induced liver injuries between September 2004 and December 2007 (Chalasanani et al., 2008). They suspected single prescription drugs in 73% (217/300; 72 cases/year) of DILI, multiple agents in 18% (55/300; 18 cases/year), and DS in 9% (28/300; 9 cases/year). The most common single causative drug was the antibiotic amoxicillin-clavulanate (combination drugs do not undergo FDA clinical studies because each drug has already been tested), followed by isoniazid and then non-steroidal anti-inflammatory drugs (Leise et al., 2014). Acetaminophen cases, responsible for almost half of acute liver failures, were excluded from the calculations, which inflates the DS percentage. Also, the 9% of DS cases reported by Chalasanani et al. (2008) involved a total of 28 supplements, but 7 (25%) of these contained illegal anabolic steroid-like substances for muscle enhancement. Excluding these products results in a more accurate estimate of DSILI cases, at 7% (21/300; 7

cases/year). If liver injuries from all causes were included, and not just those caused by drugs and/or DS, then the percentage of liver injuries from DS would be even lower.

Even fewer DSILI were observed in Spain, where only 2% (11/570) of DILI cases were associated with DS (1994–2004) and 81% (461/570) were related to drugs (Andrade et al., 2005). In Iceland, Björnsson et al. (2013) reported that the crude annual DILI rate was 19.1/100,000 inhabitants with amoxicillin-clavulanate most commonly implicated based on their prospective study of 96 patients. Italy's DILI rate was estimated to be 1.3% (136/10,270) in an 11-year retrospective study (2000–2011) (Licatta et al., 2014).

6.3. Prevalence of acute liver failure leading to liver transplant or death

The most serious DILI, which result in liver transplant and/or death, are significantly more likely to be caused by drugs than DS. Among 446 cases of liver disease in a Spanish study (1984–2004), drugs resulted in 5 liver transplants and 15 deaths, whereas medicinal herbs were implicated in no liver transplants and 1 death (Andrade et al., 2005). In essence, over this 10-year period there were 1.5 deaths a year and a liver transplant every other year due to drugs, but only 1 death and 0 liver transplants due to herbs. In the United States, Chalasani et al. reported 13 liver transplants resulting from DILI (6%; 13/217), compared to 1 liver transplant due to DSILI (4%; 1/23), for the 3.25-year period between 9/2004 and 12/2007 (Chalasani et al., 2008). More importantly, while 11% (23/217) of DILI resulted in death, none of the DSILI did. A DILIN prospective study by Chalasani et al. (2015) reported that 10% of the 899 patients underwent a liver transplant (4%) or died (6%) within 6 months. These cases appear to be drug related, as DS were not mentioned as contributing to serious events.

Russo et al. investigated the number of drug-induced acute liver failures resulting in transplantation by reviewing records for 1990 to 2002 from the United Network for Organ Sharing liver transplant database (Russo et al., 2004). Of the 2,291 transplant cases, 15% or 357 were due to acute hepatic necrosis from drugs (range 8–20%/year). Of these, 270 met criteria for inclusion in their study, and acetaminophen was responsible for approximately half of acute liver failures (46%; 124/270). Non-acetaminophen cases were primarily due to other drugs (51%; 137/270); only 7 cases (5.1%) in a 12-year period were attributed to herbs—three of these were kava–kava, chaparral tea, and vitamin A. That amounts to one DS-related liver transplant case every 4 years. When the entire 357 DILI cases are included (and not just the 270 not related to acetaminophen), 97% are attributable to drugs, but only 3% to DS.

The DILIN's goal was to quantify the number of DILI in the United States. In 2014, Fontana and associates evaluated the records of the first 660 cases of DILI from the DILIN and reported that 62 of these cases resulted in liver transplant or death (Fontana et al., 2014). Of these, 52 DILI cases (8% of 660) comprised 22 liver transplants, 9 liver failure deaths, and 4 non-hepatic deaths. The 10 cases (1.5% of 660 DILI) associated with DS resulted in 8 liver transplants, 1 liver failure death, and 1 non-hepatic death. These cases occurred over a period of 7 years (9/2004–6/2011), so the average numbers of liver transplants and deaths per year for drugs were 3.1 and 1.3 respectively, while numbers per year for DS were 1.1 and 0.14.

It is not known how many of these liver transplants and deaths were due to illegal anabolic steroids because a full list of DS products implicated was not provided in the article (Chalasani et al., 2008, 2015; Fontana et al., 2014). The prevalence of DSILI

would be even lower if products containing anabolic steroids were excluded—as they should be because these known liver toxins are controlled substances that cannot be sold without a prescription, and products that contain them are not legal DS. Without distinguishing legal DS from adulterated products, one cannot calculate an accurate annual incidence or prevalence of DSILI and/or DS-related transplants and deaths. In an earlier DILIN study reviewing 300 subjects, 26% (7/27) of the implicated DS appeared to be designer anabolic steroids (Chalasani, 2008). Extrapolating that to the 10 cases in Fontana's (2014) study, removing 26% (2.6 cases) would result in only 7.4 cases of liver transplant or death over 7 years to equal 1 case a year.

Considering the broader picture, the American Liver Foundation estimates there are 6000 + liver transplants a year (www.liverfoundation.org), and Table 2 reveals that almost half are due to hepatitis C and alcoholic liver disease (Luu, 2014). The overall contribution of DS to liver transplants and deaths compared to pharmaceuticals is minimal, but both become significantly smaller in comparison to all other causes of liver transplants.

7. DILI and DSILI prevalence in Asia, Africa, South America, and other areas

A real concern is the apparently higher rate of DSILI in certain countries, especially in areas where traditional medicine is an integral part of society that has been practiced for thousands of years.

After Ayurvedic (Indian) medicine, one of the oldest traditions of herbal medicine originated in China, where it was practiced for thousands of years BC (Stickel and Shouval, 2015). Attributing liver injuries to a particular Chinese herb is difficult because Traditional Chinese Medicine (TCM) administers mixtures of several different herbs. Over 13,000 mixed herbal preparations exist, making it difficult to identify either the active component or the causative agent contributing to liver injury (Stickel and Shouval, 2015).

In China, a database search (1994–2011) found the top four causes of DILI to be tuberculostatics (31%), the broad category of complementary and alternative medicines (CAMs) (19%), antibiotics (9%), and NSAIDs (5%) (Zhou et al., 2013). A retrospective study of 138 DILI patients in China (2008–2010) found that Chinese herbal medicines (54%; 74/138), antibiotics (8%; 11/138), and dietary supplements (6%; 9/138 or 4–5 yearly) were primarily responsible (Lai et al., 2012). Korea had even higher rates of DS-related liver injuries at 70% as reported by Suk et al. (2012), who evaluated 371 cases reported by 17 different hospitals between 2005 and 2007. However, they admitted that their broad classification of various “herbal medications or preparation,” “health foods or dietary supplements,” and “folk remedies” “was a difficult and often a vague process” (Suk et al., 2012). Even then, their rate of combined drug- and DS-related deaths and liver transplants was low at 2% (7.42 cases/3 years or 2.47 cases annually). A retrospective study analyzing the 16,696 adverse events (due to conventional medicines, CAM, and cosmetics) in the Singapore Pharmacovigilance database (1998–2009) found that approximately 3.8% were due to CAM products (Patel et al., 2012). The majority of DS cases were for sexual performance preparations (46.4%; 291/627), followed by pain remedies (5.9%; 36/627) and weight-loss aids (4.3%; 27/627). Overall, approximately 52 adverse event cases including 2 deaths per year were due to CAM (1 death a year due to hepatotoxicity). Hypoglycemia was the number one CAM-associated adverse event (46%; 288/627), suggesting that potent hypoglycemic agents from plant

Table 2
Most common causes of liver transplant in the United States.

Medical condition	Percent	Estimated number of 6,000 liver transplants a year
Hepatitis C virus	30	1,800
Alcoholic liver disease	18	1,080
Idiopathic/autoimmune	12	720
Primary biliary cirrhosis	10	600
Primary sclerosing cholangitis	8	480
Acute liver failure	7	420
Hepatitis B virus	6	360
Metabolic liver disease (inborn errors of metabolism)	3	180
Cancer	3	180
Other	3	180

(Source: Luu, 2014)

sources may compete with metformin, one of the most popular oral hypoglycemic drugs for diabetes, and a medication itself originating from the French lilac plant (*Galega officinalis*).

The prevalence of DILI is difficult to accurately assess, and the prevalence of DSILI is even more so. Studies reporting on their prevalence are very limited, vary widely in methodology, and may include or exclude acetaminophen cases—preventing consistent comparisons. Further complicating matters, plant names and uses vary among geographical regions and DS are defined differently or are pooled under the less defined and broader CAM category. As a result, rates of DILI, and especially DSILI, are not readily determined.

8. Creating DS Toxic Tables

An online “DS Toxic Table” providing a summary of potentially life-threatening, hepatotoxic DS based on a thorough review of PubMed case reports has been previously unavailable in the United States. The goal of this research review was to create a “Toxic Table” summarizing the DS case reports reported in PubMed associated with liver injuries.

LiverTox.nih.gov does list selected drugs and DS associated with liver injuries, but the list is not yet complete, herbs not associated with liver injuries are included, and it is not summarized in tabular form. One review found that 60 different herbs, herbal drugs, and herbal DS (non-herb DS were not included) were related to liver injuries (Teschke et al., 2012). In contrast, the purpose of this publication was to create a series of online “DS Toxic Tables” based on case reports (reviews not included) related to liver, kidney, heart, & cancer cases that could then receive ongoing, immediate updates, along with offering a standard DSILI reporting form for clinicians that could be written up in coauthorship with the present author to be quickly published in PubMed.

This virtual online table can now be updated by researchers with each newly reported case report in order to provide immediate awareness of potentially hepatotoxic DS (link) (Tables 3 and 4). This will be the “first online review article” that can be updated with emerging research reports, and will serve as a template for other review articles facing the constant challenge of being outdated by the date of publication. These “DS Toxic Tables” can be used to forewarn consumers, clinicians, and manufacturers.

9. Methods: literature search

Documented PubMed case reports (1966 to June, 2016, and cross-referencing) of DS appearing to contribute to liver toxicity

were listed in “DS Toxic Tables.” The broad search included the keywords of “plant extracts” or “plant preparations” with “liver toxicity” and “toxicity” [“human” species always checked]. The narrowed search included the keywords of “herb” or “dietary supplement” (combined with “liver” to generate an overview list, and possibly “toxicity” to narrow the selection. Specific herb “names” found through this process were combined with “liver toxicity.” “Hepatotoxic” “herbs” or “supplement” or “dietary supplement” were searched for more precise articles. The letter “s” was added or removed to herb or dietary supplement to generate the greater abstract number. Case reports were excluded if they involved herb combinations (some exceptions), Chinese herb mixtures, teas of mixed herb contents, mushrooms, poisonous plants, self-harm, excessive doses (except vitamins/minerals), legal or illegal drugs, drug–herbal interactions, and confounders of drugs or diseases. Since commercial dietary supplements often include a combination of ingredients, they were treated separately. Lastly, a third table of case reports consists of publications including insufficient data to assess DSILI. The spectrum of herb-induced liver injuries researched included elevated liver enzymes, hepatitis, steatosis, cholestasis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, veno-occlusive disease, acute liver failure requiring a liver transplant, and death. Only the most serious liver injuries were listed (e.g., elevated enzymes, fatigue, abdominal pain, dark urine, etc. were not always listed). English articles were the primary focus, but some reports in other languages were considered.

10. Results: DS-Related liver injuries

Approximately 21 herbs were related to liver injury case reports that include, but are not limited to: aloe vera (*Aloe barbadensis*), arrowroot juice (*Maranta arundinacea* & others?), black cohosh (*Actaea racemosa*), cascara (*Cascara sagrada*), celandine (*Chelidonium majus* L.), chaparral (*Larrea divaricate*), comfrey (*Symphytum officinale*), fo-ti (*Polygonum multiflorum*), gota kolu (*Centella asiatica*), green tea extract (*Camellia sinensis*), groundsel (*Senecio vulgaris*), Hathisunda (*Heliotropium eichwaldii*), Impila (*Callilepis laureola*), Jin bu huan (*Lycopodium serratum*), kava (*Piper methysticum*) extract, pennyroyal (*Mentha pulegium*), rattlebox (*Crotalaria sessiliflora*), senna (*Cassia angustifolia*), skullcap (*Scutellaria lateriflora*), thistle (*Atractylis gummifera*), and valerian (*Valeriana officinalis* L.). Two additional herbs, Germander (*Teucrium chamaedrys* L.) and usnic acid (*Usnea lichens*), are no longer allowed for sale in the United States. Approximately 12 DS were related to liver injury case reports that include, but are not limited to: Bakuchi tablets, conjugated linoleic acid (CLA), Euforia, Exilis, glucosamine/chondroitin, Herbalife®, Inneov masa capilar®, Kalms Tablets, Lipolyz® or Somalyz, Move Free Advanced, Pro-Lean, Sennomotokounou, and

Table 3
Herb induced liver injuries reported in PubMed^a.

Common name	Scientific name	Suggested Active compounds	Uses	Herbal Induced liver injury (HILI)	References
Aloe Vera	<i>Aloe barbadensis</i>	Anthraquinones	Laxative, gastric problems, aging, general well being	Elevated ALT and AST, jaundice, acute hepatitis	Belfrage and Malmström, 2008 Bottenberg et al., 2007 Curciarello et al., 2008 Kanat et al., 2006 Lee et al., 2014 Rabe et al., 2005 Yang et al., 2010 Kim et al., 2009
Arrowroot Juice	<i>Maranta arundinacea</i> , but several plants serve as sources including <i>Zamia integrifolia</i> , <i>Pueraria lobata</i> (kuzu in Japan)	Unknown	Treating diarrhea (10 ml 3x/day) (Cooke et al., 2000)	Hepatitis in two cases in Korea (source of arrowroot may be different, possibly kuzu)	
Black Cohosh	<i>Actaea racemosa</i>	Triterpenes glycosides and polyphenols	Menopause, hot flashes	Acute hepatitis, necrosis, fibrosis, encephalopathy, liver transplant and death The Dietary Supplement Information Expert Committee determined that black cohosh products should be labeled to include a cautionary statement (Mahady et al., 2008)	Chow et al., 2008 Cohen et al., 2004 Enbom et al., 2014 Guzman et al., 2009 Joy et al., 2008 Levitsky et al., 2005 Lontos et al., 2003 Lynch et al., 2006 Muqheet Adnan et al., 2014 Nisbet and O'Connor, 2007 Pierard et al., 2009 van de Meerendonk et al., 2009 Vannacci et al., 2009 Whiting et al., 2002
Black Cohosh Note: In 2008, a significant number of hepatotoxic cases (approximately 30) came to the attention of the Dietary Supplement Information Expert Committee of the US Pharmacopeia's Council of Experts. Their review stated that black cohosh products should be sold with a cautionary statement indicating that hepatotoxicity is possible (Mahady et al., 2008). A previous 2002 review required no such statement showing that sometimes a significant period of time must pass for a sufficient number of cases to surface before action is taken. Thirteen additional cases were reported in 2009 (Mahady et al., 2009), and another review is provided by Teschke, 2010a.					
Cascara	<i>Cascara sagrada</i>	Anthracene glycoside	Laxative	Fibrosis, hepatitis	Jacobsen et al., 2009 Nadir et al., 2000
Chaparral	<i>Larrea divaricata</i>	Nordihydroguaiaretic acid (NDGA)	Cancer (melanoma), bronchitis, colds, rheumatic pain, stomach pain, and chicken pox.	Hepatitis, liver toxicity, liver failure. 13 cases of hepatitis reported to FDA between 1992–94. Removed from the GRAS list in 1970.	Alderman et al., 1994 Batchelor et al., 1995 CDC, 1992 Gordon et al., 1995 Katz and Saibil, 1990 Kauma et al., 2004 Shad et al., 1999 Sheikh et al., 1997 Smith and Desmond, 1993
Chinese Herbs (single herbs only as herb combinations were excluded)					
Fo-ti (called Shou Wu Pian when combined with other herbs)	<i>Polygonum Multiflorum</i>	Anthraquinones	Hair growth, gray hair prevention, restore youthful vigor, prostatitis, constipation, erectile dysfunction, cancer.	18 cases of jaundice. Hepatitis (numerous cases of hepatitis reported with Shou Wu Pian)	Banarova et al., 2012 Dong et al., 2014 Berringer et al., 1999
Celandine (Greater celandine)	<i>Chelidonium majus L.</i>	Isoquinoline alkaloids	Externally for skin conditions (warts, eczema); internally for liver, gallstones, irritable bowel syndrome	Cholestatic hepatitis	Crijns et al., 2002 Hardeman et al., 2008 Moro et al., 2009 Rifai et al., 2006 StickeI, 2006 Strahl et al., 1998
Comfrey	<i>Symphytum officinale</i> <i>Symphytum asperum</i>	Pyrrrolizidine alkaloids ^b	Internally for blunt injuries (bruises, sprains, and broken bones), digestive tract problems (ulcers, diarrhea, inflammation), rheumatism and pleuritis. Externally as a gargle for gum disease, pharyngitis, and strep throat.	Veno-occlusive disease, tends to lack symptoms of jaundice or increased liver enzymes	Bach et al., 1989 Ridker et al., 1985 Weston et al., 1987 Yeong et al., 1990
Comfrey Notes: The sale of comfrey is banned in Canada and Germany, but not the United States (StickeI et al., 2005)					
Germander	<i>Teucrium chamaedrys L.</i> <i>Teucrium polium</i> <i>Teucrium viscidum</i>	Diterpenes	Weight loss, gout, digestive aid, fever. Most of those affected were ingesting 600	Hepatitis, liver transplant, and death. Total of 52 + cases. Includes the 26 hepatitis cases in France	Ben Yahia et al., 1993 Castot and Larrey, 1992 Dao et al., 1993 Diaz et al., 1992

(continued on next page)

Table 3 (continued)

Common name	Scientific name	Suggested Active compounds	Uses	Herbal Induced liver injury (HILI)	References
			–1600 mg/day for 2 months (Stickel et al., 2005).	where germander was banned in 1992 (Castot, 1992). Most recovered, but there were two cirrhosis cases, 1 liver transplant and 1 death (Gori et al., 2011).	Dourakis et al., 2002 Goksu et al., 2012 Gori et al., 2011 Laliberte and Villeneuve, 1996 Larrey et al., 1992 Legoux et al., 1992 Mattéi et al., 1995 Mattéi et al., 1992 Mazokopakis et al., 2004 Mimidis et al., 2009 Mostefa-Kara et al., 1992 Nencini et al., 2014 Pauwels et al., 1992 Pérez Alvarez et al., 2001 Polymeros et al., 2002 Poon et al., 2008 Savvidou et al., 2007 Sezer and Bozaykut, 2012 Starakis et al., 2006
Gota Kolu	<i>Centella asiatica</i>	Pentacyclic triterpenic saponosides	Weight loss	4 cases of hepatitis with 2 positive rechallenges	Dantuluri et al., 2011 Jorge and Jorge, 2005
Green Tea Extract	<i>Camellia sinensis</i>	Catechins - epigallocatechin-3-gallate (EGCG)	Weight loss	Hepatitis, 2 liver transplants. 34 reports - 27 cases possible, 7 probable (Sarma et al., 2008).	Abu, 2005 Bonkovsky, 2006 García-Cortés et al., 2008 (3) Gloro et al., 2005 (LT) Molinari et al., 2006 (LT) Patel et al., 2013 Pedrós et al., 2003 Pillukat et al., 2014 Sarma et al., 2008 (27)
Green Tea Extract Note: See Hydroxycut and other dietary supplements containing green tea extract. Exolise [®] , a weight loss supplement, was withdrawn from the market in France and Spain due to hepatotoxicity (Weinstein, 2012).				19 cases (2 listed here) were summarized by Mazzaniti (2015) with 11 possible cases and 8 probable (CIOMS/RUCAM). Four were beverage based. All recovered except 2 with declining labs, and the 4 liver transplants were patients taking multiple ingredients. Ten cases were primarily green tea/extract. 44 yr female with acute liver failure followed by transplant taking 720 mg/day for weight loss (Molinari, 2006) Two cases of green tea drinks: 1) 51 yr female drinking unknown cups/day for 5 years with elevated enzymes and positive rechallenge (Federico, 2007), 2) 45 yr male drinking 6 cups a day for 4 months with hepatitis and positive rechallenge (Jimenez-Saenz, 2006)	
Groundsel	<i>Senecio vulgaris</i> <i>Senecio longilobus</i>	Pyrrrolizidine alkaloids	Traditional medicinal teas in Mexico, Jamaica, Afghanistan, India. Constipation, colic, epilepsy, worms. Not recommended for internal use due to its toxic and carcinogenic pyrrrolizidine alkaloids.	Ascites, hepatitis, veno-occlusive liver disease, infant death	Fox et al., 1978 Ortiz Cansado et al., 1995 Stillman et al., 1977 (D) Vilar et al., 2000
Impila	<i>Callilepis laureola</i>	Atractylsides	Traditional Zulu remedy that means "good health." Ward off evil spirits in children. About 44% of deaths in	Hypoglycemia and prolonged prothrombin times are universal symptoms. Leucocytosis (80%), acidic breathing (73%),	Steenkamp et al., 1999 Wainwright et al., 1977 Watson et al., 1979

Table 3 (continued)

Common name	Scientific name	Suggested Active compounds	Uses	Herbal Induced liver injury (HILI)	References
Jin Bu Huan (JBH)	<i>Lycopodium serratum</i>	Levo-tetrahydropalmatine; Pyrrolizidine alkaloids	Traditional Chinese Medicine used as a sedative sleeping aid, analgesic, and for indigestion.	convulsions (52%), coma (40%), diarrhea or vomiting (40%), jaundice (13%), elevated enzymes (Watson et al., 1979). Acute liver and renal failure. Acute fatal hepatocellular necrosis, especially in children. Death.	Brent, 1999 Horowitz et al., 1996 Picciotto et al., 1998 Woolf et al., 1994 Brauer et al., 2003 Bujanda et al., 2002 CDC, 2002 Christl et al., 2009 Escher et al., 2001 Gow et al., 2003 Humberston et al., 2003 Kraft et al., 2001 Russmann et al., 2001 Stickel et al., 2003a,b Strahl et al., 1998 Anderson et al., 1996 (3) Bakerink et al., 1996 (D) Sullivan et al., 1979 (D)
Kava	<i>Piper methysticum</i>	Kava lactones (kava pyrones)	Anxiety and insomnia. Traditional use as a cultural beverage in Polynesia. A review of kava cases is provided by Teschke, 2010b.	Acute hepatitis necrotizing hepatitis, cholestatic hepatitis, lobular hepatitis, fulminant hepatic failure, liver transplant, death. Consuming alcohol with kava may be a triggering factor.	
Pennyroyal (American or European)	<i>Mentha pulegium</i>	Pulegone	Oil or tea leaves used in Hispanic cultures to treat colic, stimulate menses, & induce abortion.	Rapid onset. Elevated liver enzymes, liver necrosis, coma, death (especially in infants & young women)	
Rattlebox	<i>Crotalaria sessiliflora</i> <i>Crotalaria longirostrata</i> <i>Crotalaria (species)</i>	Pyrrolizidine alkaloids	Chinese remedy for cancer. Seeds sometimes accidentally mixed with foods in India, China, South America, and other countries. Teas in Mexico.	Chronic diarrhea, cirrhosis, liver necrosis, biliary hyperplasia, fibrosis, veno-occlusive disease, hepatomegaly, death	Guan, 2006 Lyford et al., 1976 Ng, 2014 Tandon et al., 1976
Saw palmetto	<i>Serenoa repens</i>	Estrogenic and antiandrogenic effects (Jibrin et al., 2006)	Benign prostate enlargement	58 yr male with elevated enzymes and enlarged liver and history of Gilbert's syndrome taking 900 mg of dried extract + 660 mg of berry powder. Symptoms decreased when stopping supplement.	Lapi et al., 2010
Senna	<i>Cassia angustifolia</i>	Menthofuran Anthraquinones	Laxative	Hepatitis, liver necrosis. Positive re-exposure (Beuers et al., 1991)	Beuers et al., 1991 Seybold et al., 2004 Sonmez et al., 2005 Vanderperren et al., 2005
Skullcap	<i>Scutellaria lateriflora</i>	Cytotoxic flavonoids	Anxiety, insomnia	Hepatitis, liver failure and death	Estes et al., 2003 (LT) Hullar et al., 1999 (LT,D)
Thistle (Blue, glue, pine or Mediterranean thistle)	<i>Atractylis gummifera</i>	Diterpenoid glucosides	Stomach aches and stomach ulcers. Common cause of accidental poisoning in Mediterranean children eating plants. Thistle looks like wild artichoke and the root is like a chewing gum	Severe hepatitis, necrosis, liver failure, liver transplant, death	Caravaca-Magarios et al., 1985 Catanzano et al., 1969 Georgiou et al., 1988 (D) Lemaigre et al., 1975 Hamouda et al., 2004 Hamouda et al., 2000
Usnic acid	<i>Usnea lichens (fungi & algae)</i>	Usnic acid extracted from lichens	Traditional Chinese antimicrobial agent (Guo et al., 2008). Weight loss – popular ingredient in fat burner formulations that increase metabolism and thermogenesis.	Liver transplant. FDA received 21 of liver toxicity from dietary supplements containing usnic acid (Guo et al., 2008). See dietary supplements LipoKinetix and UCP-1.	Durazo et al., 2004 LT
Valerian	<i>Valeriana officinalis L.</i>	Valeric acid	Anxiety, insomnia	Acute hepatitis, hepatomegaly (no jaundice), liver Fibrosis	Cohen and Del Toro, 2008 Vassiliadis et al., 2009
Add a DSILI case report not on the list or make comments/corrections					
New herb	New	New	New	New	New

Shaded herbs no longer sold on the internet.

© 2017 Amy Christine Brown. All Rights Reserved.

^a These case reports are compiled from published papers in the scientific literature. Commercial formulations may have changed.

^b Pyrrolizidine alkaloids (PA) exhibit a clear dose-dependent hepatotoxicity and are banned in Europe and North America (Stickel and Shouval, 2015). PA's can be classified into saturated and unsaturated, with the latter being well-known hepatotoxic and carcinogenic compounds. They generate toxic metabolites resulting in hepatic veno-occlusive disease and/or liver cancer (Fu et al., 2004; Lin, 2009). PA are likely the responsible liver toxicity agents for comfrey, groundsel, Hathisunda, and Jin Bu Huan. Children in South Africa and Jamaica have developed ascites, hepatomegaly and cirrhosis after drinking "bush tea" (Stickel, 2005). Reviews of PA-containing plants are provided by Roeder, 2000 and Chojkier, 2003.

UCP-1 (Table 4). Niacin (nicotinic acid) and vitamin A were not counted because these DS due to excess intakes. Nine additional DS (or older formulations) are no longer sold in the United States including anabolic steroids, Flavocoxid, Hydroxycut, LipoKinetix[®], OxyElite Pro[®], Sennomotokounou, Venencapsan[®], venoplant, and usnic acid. The names, ingredients, and corporations of dietary

supplements can change so those listed here may not reflect current products on the market. The DS with the most number of reported publications, but not always cases studies, in descending order, were germander, black cohosh, kava extract, and green tea extract.

Table 4
Dietary supplement induced liver injury cases reported in PubMed and by FDA^a.

Common name	Suspected substance ^a (formulations often changed)	Uses	Dietary supplement Induced liver injury	References
Bakuchi tablets	Psoralea corylifolia leaves with psoralens	Vitiligo	64/F with severe hepatotoxicity via elevated liver enzymes. CIOMS probable score 8	Teschke and Bahre, 2009
Anabolic steroids	Illegal class III controlled substances.			
<p>Note: Anabolic steroids. These are not legal DS so case reports are not listed. The abuse of anabolic androgenic steroids led them to being classified as controlled substances by The Anabolic Steroid Control Act of 1990 (Krishman, 2009). It is illegal to possess, manufacture, distribute or dispense them unless it is for strict medical purposes such as androgen deficiency, rare forms of aplastic anemia, and counteracting catabolic states such as trauma and HIV wasting (Kafrouni et al., 2007; Krishman, 2009). Liver injury includes peliosis hepatitis, benign or malignant neoplasms, cholestasis, and if prolonged, nephropathy (Krishman, 2009). Many anabolic steroids have been related to hepatotoxicity cases (Kafrouni et al., 2007; Krishnan et al., 2009; Shah et al., 2008).</p> <p>The Anabolic Steroid Control Act of 1990 may be too specific in listing anabolic steroids because chemists can alter a known steroid to create a new one to circumvent controlled substance laws and avoid detection through standard drug screens (Rahnema et al., 2015). These “designer steroids” have shifted from being sold on the black market to certain body-building dietary supplements. Sport officials become aware of the new steroids, the FDA rarely bans them, and manufacturers are rarely penalized (Shipley et al., 2005). If the FDA does ban them and or “related substances,” a new designer steroid can be made. If the designer steroid is not on the label, the manufacturer is also violating labeling laws.</p>				
Conjugated linoleic acid (CLA)	Conjugated linoleic acid	Weight loss	26 yr female with hepatitis 63 yr female with fulminant hepatic failure requiring transplant; 46 yr female with jaundice, and confirmed liver biopsy	Bilal et al., 2015 Nortadas and Barata, 2012 Ramos et al., 2009
Euforia	Acai berry, mangosteen, Aloe vera, resveratrol, curcumin, black seed, blueberry, pomegranate, green tea, noni, goji	Anti-inflammatory and antioxidant	45 yr female with necrosis and hepatitis; 8.8% of systemic sclerosis have liver damage, but she had a positive rechallenge taking 2 ounces daily	Jiménez-Encarnación et al., 2012
Exilis	Similar to Hydroxycut – Green tea extract, <i>Garcinia cambogia</i> , <i>Gymnema sylvestre</i> , and others	Weight loss Other products may be on the market that mimic Hydroxycut's formulation that was removed from the market.	25 yr male with elevated enzymes, nausea, vomiting, fatigue, fulminant hepatic failure, & liver transplant. Took Exilis for two weeks.	McDonnell et al., 2009
Flavocoxid (Limbrel)	Proprietary blend of 2 flavonoids, baicalin and catechins derived from <i>Scutellaria baicalensis</i> (Skullcap related to liver injuries), and Acacia catechu	Medical food requiring a prescription for osteoarthritis	4 patients with elevated liver enzymes in DILIN study	Chalasani et al., 2012 (4)
Glucosamine &/or Glucosamine chondroitin		Osteoarthritis	28/F with jaundice, hepatitis and itching after taking glucosamine for 1 month. Elevated enzyme levels normalized after withdrawal. 56/F with elevated enzymes. 55 yr female with elevated enzymes and jaundice after 2 weeks on glucosamine. 52 yr male with elevated enzymes and itching after 3 weeks of glucosamine. 64 yr male with jaundice, acute renal failure, fulminant hepatic failure, and death after taking glucosamine and chondroitin sulfate for 4 weeks. 57 yr female with jaundice and chronic hepatitis after taking glucosamine for 4 weeks.	Cerda et al., 2013 Ebrahim et al., 2012 Ossendza et al., 2007 Smith, 2009
<p>Glucosamine Notes: Glucosamine can be sold as is or more commonly available in a variety of commercial preparations that combines it with chondroitin sulfate, MSM (methylsulfonylmethane), manganese ascorbate, or cartilage (shark or bovine). The glucosamine itself comes in a variety of types (eg, glucosamine sulfate, glucosamine hydrochloride, and <i>N</i>-acetylglucosamine) in tablet, capsule, powder or liquid form (Smith and Dillon, 2009). One survey of 150 chronic liver disease patients showed that 15% (23/150) were taking glucosamine and/or chondroitin sulfate (Cerda et al., 2013).</p>				
Green Tea Extract	<i>Camellia sinensis</i> Catechins - epigallocatechin-3-gallate (EGCG)	Weight loss	Hepatitis, 2 liver transplants. 34 reports - 27 cases possible, 7 probable (Sarma et al., 2008).	Abu el et al., 2005 Bonkovsky, 2006 García-Cortes, 2008 (3)

Table 4 (continued)

Common name	Suspected substance ^a (formulations often changed)	Uses	Dietary supplement Induced liver injury	References
Green Tea Extract	Notes: Catechins are implicated in liver toxicity, but 40% (29/73) of DS products analyzed for catechins did not identify green tea extract on the label which is a violation of current labeling laws (Navarro and Seeff, 2013).		19 cases (2 listed here) were summarized by Mazzanti (2015) with 11 possible cases and 8 probable (CIOMS/RUCAM). Four were beverage based. All recovered except 2 with declining labs, and the 4 liver transplants were patients taking multiple ingredients. Ten cases were primarily green tea/extract. 44 yr female with acute liver failure followed by transplant taking 720 mg/day for weight loss (Molinari et al., 2006) Two cases of green tea drinks: 1) 51 yr female drinking unknown cups/day for 5 years with elevated enzymes and positive rechallenge (Federico et al., 2007), 2) 45 yr male drinking 6 cups a day for 4 months with hepatitis and positive rechallenge (Jimenez-Saenz and Martinez-Sanchez Mdel, 2006)	Gloro et al., 2005 (LT) Molinari et al., 2006 (LT) Patel et al., 2013 Pedros, 2003 Pillukat et al., 2014 Sarma et al., 2008 (27)
Herbalife [®]	Notes:		Numerous products with variable ingredients - pills, powders, shakes, teas, bars, etc.	Well-being, weight loss, nutritional support
63 yr F with hepatitis	Chao et al., 2008			
Over 34 Herbalife [®] cases from at least 5 countries since 2007 have been reported (Stickel et al., 2011). Another review retrieved 53 cases of which 8 had a positive unintentional reexposure (Teschke et al., 2013b). Many ingredients are in each Herbalife [®] product, and customers tend to take more than one product. Appelhans et al. (2011) states numerous reasons why Chen's (2010) 3 case reports are not scientifically supported, including that Herbalife [®] is not a single product, and that there was insufficient information on patient histories, dosage/frequency, concomitant medications, and product ingredients. Five plus other articles defending Herbalife can be found in PubMed under Appelhan's authorship.			37/F with jaundice 53/F with jaundice 3 cases of hepatotoxicity in Spain. 12 patients identified in Israeli hospitals by Ministry of Health. Hepatitis resolved in 11 patients, one succumbed to complications following liver transplant. Three experienced 2nd bout of hepatitis after rechallenge. 56 yr F with hepatitis and necrosis. Noni also consumed (see below) Five cases in Iceland: elevated liver enzymes and 2 with hepatitis. RUCAM = probable in 3, possible in 2. WHO criteria = certain in 1, probable in 2, possible in 2 A search of Spanish Pharmacovigilance Centres (2003–2010) revealed 20 cases, 12 required hospitalization, 9 were jaundiced, 2 experienced positive rechallenge. Karch and Lasagna scale = 1 definite, 14 probable, 5 possible. Two cases of probable cause and a fatality. Ten cases of hepatitis detected by a questionnaire sent to all Swiss hospitals (1998–2004). Liver biopsy showed hepatic necrosis, marked lymphocytic-eosinophilic infiltration, and cholestasis in 5 patients; 1 with fulminant liver failure and transplant. CIOMS = certain in 2, probable in 7, possible in 1.	Chen et al., 2010 Duque et al., 2007 Elinav et al., 2007 Garrido-Gallego et al., 2015 Jóhannsson et al., 2010 Manso et al., 2011 Mengual-Moreno, 2015 (2) Schoepfer et al., 2007 Stickel et al., 2009

(continued on next page)

Table 4 (continued)

Common name	Suspected substance ^a (formulations often changed)	Uses	Dietary supplement Induced liver injury	References
Hydroxycut [®]	Numerous formulations with different ingredients: <u>Green tea extract</u> ; <u>Garcinia cambogia</u> (hydroxycitric acid); <u>Ma huang</u> extract (ephedra) (Bajaj et al., 2003) <u>Cissus quadrangularis</u> (toxic to animals) (Barakat et al., 1985); 2000 formula = hydroxagen?, guarana extract, L-carnitine, ma huang extract, willow bark extract, chromium picolinate (Kockler et al., 2001)	Weight loss and body building (See Elixis above)	Two patients with hepatitis and cirrhosis respectively after ingesting bacterially (<i>Bacillus subtilis</i>) contaminated products. CIOMS = probable. 41/M with jaundice taking Newer version Hydroxycut [®] , SX-7 Clean Sensory	Araujo and Worman, 2015
Hydroxycut [®] Notes:	Hydroxycut [®] was withdrawn by its manufacturer after a May 1, 2009 warning issued by FDA for its possible role in 23 cases of hepatotoxicity reported via MedWatch (Sarma, 2010). Lobb (2009) published a review on hepatotoxicity cases related to Hydroxycut [®] . Hydroxycut [®] was named after one of its ingredients, hydroxycitric acid, an extract from <i>Garcinia cambogia</i> (Stohs et al., 2009). In 2009, fourteen different Hydroxycut [®] formulations containing up to 20 different ingredients existed. Eight of the 14 formulas contained hydroxycitric acid. Semwal et al. (2015) provides a comprehensive review of <i>Garcinia cambogia</i> , while Stohs et al. (2009) and Soni et al. (2004) summarize studies supporting Hydroxycut [®] s [®] and hydroxycitric acid's safety respectively. Stohs and Ray (2013) also supported the safety of <i>Cissus quadrangularis</i> .		31/F with jaundice resolved within 2 weeks 40/F on 6 pills daily with elevated liver enzymes. 33/F with jaundice 8 patients at different medical centers; 3 required liver transplants; 1 death. /M Army soldier with jaundice 23, 25, 25 yr males in the military on Hydroxycut with liver biopsies revealing acute hepatitis, steatosis, and cholestasis respectively. 23/M with jaundice on Hydroxycut Hardcore 28/M with jaundice 27/M with jaundice 30/M with jaundice, cholestasis 59/F on pills for 1 month with necrosis, jaundice (probable on CIOMS/RUCAM) 31/F taking pills for 1 month with elevated enzymes (highly probable)	Chen et al., 2010 Dara et al., 2008 Fong et al., 2010 Jones and Andrews, 2007 Laczek and Duncan, 2008 Rashid and Grant, 2010 Shim and Saab, 2009 Stevens et al., 2005
Inneov masa capilar [®]	Green tea extract (27–30%), grape seed catechins, taurine, & zinc gluconate.	Stop hair loss		Fernández et al., 2014
Kalms Tablets (not Calms; different product)	Skull cap, valerian (formula may have changed)	Sedative		MacGregor et al., 1989 (2)
LipoKinetix [®]	Contained norephedrine, yohimbine, 3,5-diiodothyronine, sodium usniate (See <u>usnic acid</u>), and caffeine.	Weight loss	7 cases of severe hepatotoxicity (20–32 yrs of age; 5 were Japanese) taking LipoKinetix [®] (4 on other products listed) for 10–32 days with jaundice.	Favreau et al., 2002 (7)
LipoKinetix [®] Notes:	FDA removed it from market in 2001. FDA has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix (FDA-c, 2013-c).		32 yr female with necrosis. 32 yr female with liver transplant. 24 yr female taking LipoKinetix [®] for 3 months with jaundice followed by liver transplant	Neff et al., 2004 Scott et al., 2003
Lipolyz [®] and Somalyz [®]	Fat burner Lipolyz [®] contained: Propionyl L-carnitine (500 mg), <u>green tea extract</u> (300 mg), <u>usnic acid</u> (12 mg), <u>guggulsterone</u> (10 mg) vitamin E (20 IU), C-Amp (2 mg)	Fat burner Somalyz [®] contained: <u>GABA</u> (667 mg), Propionyl L-carnitine (167 mg), phosphatidylcholine (50 mg); <u>usnic acid</u> (4 mg), melatonin (1 mg), vitamin E (20 IU)	28 yr female bodybuilder with unresponsive encephalopathy requiring liver transplant after taking two fat burners for 1 month. The underlined substances could have contributed. Although no cases appear with GABA, it is possible because Progabide, a GABA drug mimetic, resulted in severe hepatic failure after 4 weeks (Munoz et al., 1988).	Krishna, 2011
Move Free Advanced	Skullcap Glucosamine	Osteoarthritis	2 patients with hepatotoxicity that resolved upon ceasing supplement. Probable 6 on	Linnebur et al., 2010 Yang et al., 2012

Table 4 (continued)

Common name	Suspected substance ^a (formulations often changed)	Uses	Dietary supplement Induced liver injury	References
Niacin (3 gm, slow release)	Niacin, a B-vitamin	Prescribed for high blood cholesterol. Energy drinks do get that “buzz” (tingling from niacin).	Naranjo scale. 78 yr female with hepatitis. Positive re-exposure (Yang et al., 2012) 69 yr male switched from fast to slow (timed) release niacin and experienced hepatitis	Bassan, 2012
Niacin Notes:			17 yr male with acute liver failure after taking excess niacin to deter drug test. 3 cases of niacin induced hepatitis FDA review of niacin related to liver toxicity—adverse reactions in 6 on regular niacin, 2 on slow release, and 10 who switched from regular to slow (timed) release niacin. 22 yr female with acute hepatitis after consuming 10 cans of energy drink daily (contained niacin)	Ellsworth et al., 2014 Mounajjed et al., 2014 Rader et al., 1992 Vivekanandarajah et al., 2011
OxyElite Pro [®]	Version 1 DMAA (1,3-dimethylamyl-amine) (See Cardiotoxicity) Version 2 Aegeline	Weight loss, bodybuilding	7 military patients – 5 with jaundice and 1 having a liver transplant	Foley et al., 2014
	Version 2 Aegeline	Weight loss, bodybuilding	Hawaii Department of Health reporting on 29 patients in Hawaii using OxyElite Pro with 12 using only OxyElite Pro. Jaundice.	Johnston et al., 2016
	Version 2 Aegeline	Weight loss, bodybuilding	Physician review of 8 patients (all Polynesian or Asian from Hawaii that has one liver center in the state) hospitalized – 7 with jaundice, 2 with liver transplants, and 1 death. RUCAM/CIOMS scale – 7 probable, 1 highly probable.	Roytman et al., 2014
Pro-Lean	One capsule (to be taken once per day) contains ma-huang, guarana, kola nut, white willow bark, ginkgo biloba, bladderwrack, gotu kola, boron, ginseng, fo-ti, magnesium salicylate, folic acid, bee pollen, spirulina and ginger root, chromium vitamin B12, vanadium, caffeine, cyperus root extract, tyrosine.	Weight loss	20 yr female taking product for two weeks with jaundice, & hepatitis.	Joshi et al., 2007
Sennomotokounou	11 herbs: kudzu vine root, coix seed, hawthorn fruit, wolfbeery fruit, chrysanthemum flower, louts leaves, tangle kelp, radish seeds, cassia seeds, jiogulan leaf, <u>tea leaf extracts?</u>	Chinese DS for weight loss. Removed from market in Japan due to adverse hepatotoxic reactions.	63 yr female with jaundice 24 yr female with jaundice 53 yr female with elevated enzymes and dark urine 120 reports of hepatotoxicity on the Japan Ministry of Health, Labour & Welfare website (2000–2002). Hyperthyroidism should be considered as it also contains thyroid hormones, T3. 32 reports of thyroid dysfunction.	Kawata et al., 2003
UCP-1	Usnic acid, L-carnitine, calcium pyruvate	Weight loss	28 yr female on UCP-1 for 3 months. Jaundice, hepatic encephalopathy, liver transplant. 38 yr male (husband of above female) taking UCP-1 for 3 months, but also on desloratidine, famotidine, and naproxen, acetaminophen/oxycodone, cyclobenzaprine, and 120 g alcohol. Jaundice.	Sanchez et al., 2006
Venencapsan [®]		Varicose veins, hemorrhoids, and phlebitis	69 yr female with jaundice and elevated enzymes, returned	De Smet et al., 1996

(continued on next page)

Table 4 (continued)

Common name	Suspected substance ^a (formulations often changed)	Uses	Dietary supplement Induced liver injury	References
Venoplant	<u>Horse chestnut leaf</u> , milfoil, <u>celandine</u> , sweet clover, milk thistle, dandelion root. <i>Aesculus hippocastanum</i> (horse chestnut) extracts	Venous insufficiency	to normal, but jaundice returned with rechallenge. 27 yr male with jaundice, necrosis, cholestasis	Takegoshi et al., 1986
Vitamin A	Recommended daily value is 5000 IU/day. 25,000 for 6 years and 100,000 for 6 months are toxic. Children toxicity at 1500 IU/kg body weight (Penniston, 2006)		3 Chinese men consuming fish livers. Headache, dizziness, nausea, vomiting fever, skin peeling. 3 Chinese pediatric cases in New Zealand of a 2 yr female, 11 and 14 year old boys. Consumed fish livers. Headache, vomiting, abdominal pain, red, peeling rash. New Zealand Chinese fisherman ingesting fish livers. Headache, vomiting, peeling skin. male 60 yr male liver transplant after taking 500,000 IU daily for 4 months, then 100,000 IU for 6 months. Fibrosis, splenomegaly and ascites Yr male with hepatotoxicity on 25,000 IU/day 41 patients with vitamin A hepatotoxicity due to 25,000 to 100,000 daily; 6 died 52 yr female with hepatic hydrothorax. Ingested 270,000 IU daily. 3 family members with hepatotoxicity from 20,000 to 45,000 per day for 7–10 years. 4 yr female with cystic fibrosis and hypervitaminosis A 48 yr male with skin discoloration + elevated liver enzymes 59 yr male with cirrhosis ingesting 13,000 ug/day 69 yr female with hepatomegaly	Chiu et al., 1999 Hayman and Dalziel, 2012 Lonie, 1950 Castaño et al., 2006 Cheruvattath et al., 2006 Forouhar et al., 1984 Kowalski et al., 1994 Geubel et al., 1991 Miksdal et al., 2002 Minuk et al., 1988 Safi et al., 2014 Sansone and Sansone, 2012 Sheth et al., 2008 Theiler et al., 1993
Usnic Acid	<i>Usnea lichens (fungi & algae)</i> Usnic acid extracted from lichens		Fulminant hepatic failure requiring liver transplant Hepatic necrosis	Sanchez et al., 2006
Add a DSILI case report not on the list or make comments/corrections				
New DS	New	New	New	New

© 2017 Amy Christine Brown. All Rights Reserved.

Shaded dietary supplements no longer sold on the internet.

^a These case reports are compiled from published papers in the scientific literature. Commercial formulations may have changed.

11. Discussion

11.1. Herb-related liver injuries

Over the last 50 + years (1966–2015), approximately 21 herbs have been reported in PubMed to be associated with liver toxicity in case report publications. Although the number of publications does not always reflect the number of case reports, the herbs with the highest number of publications (not cases), in descending order, were (number in the last 10 years is in parentheses):

Herb	Total Publications (Per year)	Status
Germander (<i>Teucrium chamaedrys</i> L.)	– 23 (7)	No longer sold
Black cohosh (<i>Actaea racemosa</i>)	– 13 (12)	USP warning label
Kava (<i>Piper methysticum</i>) (extract)	– 10 (1)	Not admitted by USP
Green tea extract	– 9 (8)	
Chaparral (<i>Larrea divaricate</i>)	– 9 (0)	
Aloe vera (<i>Aloe barbadensis</i>)	– 7 (7)	
Greater celandine (<i>Chelidonium majus</i> L.)	– 7 (3)	
	Total = 78 (1.56 publications/year)	

Germander, the herb with the largest number of publications and usnic acid, no longer appear for sale (as a single ingredient) in a Google search (English language) as of July, 2016. The US Pharmacopeia (USP) did not admit kava into the USP-NF monograph development process due to concern with possible liver injury. Kava is no longer available in certain countries, but is sold in the United States and via the Internet. USP also suggests warning labels for black cohosh with regard to possible liver damage (Brown, 2016a). At least two published reports associate liver injury with drinking excessive quantities of green tea (not extract). Chaparral, aloe vera, and celandine are also sold on the Internet. It is recommended that the USP review these herbs for possible proper labeling statement warnings. Based on liver toxicity reports from the last ten years, and the fact that germander appears to be unavailable, black cohosh (12 publications), green tea extract (8), and aloe vera (7) currently appear to be the main potentially problematic herbs. However, in terms of quantity, these three herbs resulted in 27 publications over the last decade, or approximately 3 annual reports.

The remaining herbs had 6 or fewer publications each in the last 10 years. However, five are still sold on the Internet: fo-ti (Shou Wu Pian) has been associated with 18 cases of hepatitis; pennyroyal was implicated in two deaths, indicating that infants should not be given this herb as a colic treatment; senna is a laxative related to a liver necrosis report; skullcap was associated with 2 liver transplants and a death; and valerian was related to a liver fibrosis report.

Other herbs with serious rare implications, but not widely available on the Internet, include impila, associated with liver and kidney failure and death, especially in children; rattlebox (appears to be harvested from local plants), which should not be used in infants, especially in Mexico or the Southern states, as a death has been reported; thistle (not milk thistle), reportedly related to liver failure and death; and usnic acid extracted from lichen, which appears to no longer be sold due to liver toxicity and death reports. However, moss, lichen, and a liquid extract of unknown concentration were being sold on the Internet.

In summary, the most egregious herb, germander, is no longer for sale; the next three most prominent offenders (black cohosh, kava, and green tea extracts) have or should have designated warning labels; and the last three, chaparral, aloe vera, and greater celandine, had infrequent liver injury reports over the last 50 years and may require warning labels. Chaparral was actually removed from the GRAS list in 1970, but is still found for sale on the Internet. No liver toxicity cases attributed to chaparral have occurred in the last 10 years, which is positive news because liver failure was previously reported. Only 10 total publications involving aloe vera or greater celandine have appeared in the last 10 years. Hepatitis was the worst symptom reported, and there were no reports of liver transplant or death; nevertheless, caution may be justified. The remaining herbs have far fewer publications, but that does not negate their possible implications in liver toxicity—especially fo-ti, pennyroyal, senna, skullcap, and valerian.

Although traditional herbs from Asian, African, or other countries were not included in this review, a review of Traditional Chinese Medicine (Teschke, 2014; Teschke et al., 2016) suggests that they appear to have a higher rate of HILI. Therefore, the need to review TCM remedies for related liver injuries may be greater, and any new case reports can be inserted into the “DS Toxic Tables.” These tables document DSILI case reports, and although not all are yet included, additional past or future reports from all possible published sources may be submitted.

11.2. Dietary supplement-related liver injuries

Identifying a DS is not always an easy task. DS formulations can and often do change with or without product name changes. There are many reasons this occurs. One motivation is receiving a Warning Letter from the FDA regarding a particular ingredient. In addition, a single product name may designate a range of different products identified by sub-category names (Supplement A, Supplement A-Max, Supplement A-Max Super). As such, this review simply reports on the previously published reports of DS that may or may not represent current product names and/or ingredients. In some cases, PubMed authors did not include the DS brand name and/or other ingredients.

This review identified approximately 12 DS (minus 9 no longer sold & Vitamin A & niacin due to excess intake) related to liver toxicity in PubMed publications over the last 50 years. Only case reports were included, so a review listing DS related to liver injuries without case report information did not meet the criteria for this report. Even if such a list was provided, a DS was usually only listed once or twice, which can pale in comparison to sales. A great many factors can contribute to these single instances lacking sufficient information and thus being included in Table 5; the three most common confounding factors were underlying disease in subjects, use of mixed herbs, and inclusion of drugs. Also, approximately 24% of DS listed in previous prevalence studies were actually designer anabolic steroids—that is, illegal drugs rather than supplements.

As mentioned previously, many bodybuilding products may contain steroid substances, which are known liver toxins, and thus should be excluded from DS statistics as illegally marketed controlled substances. Under current regulations they should be removed from store shelves as well. To include DS or illegal drugs related to liver toxicity in a list of legitimate drugs related to liver toxicity is not equitable. The same applies to including drugs, especially illegal drugs, in a list of DS implicated in liver injuries. As such, steroid dietary supplements were not included in this review, nor should they be included in future reviews unless the goal is to increase the perceived harm caused by legitimate DS. Failing to mention whether anabolic steroids and other drugs are included, and in what amounts, when reporting DSILI makes assessing the degree of risk of DS more difficult to discern. Currently, when research articles that omit this information are cited in the U.S. media through press releases, a possibly unfounded bias against DS is being propagated.

11.2.1. Weight-loss products

Navarro et al. (2013) stated that DS sold for bodybuilding and weight loss are the most commonly associated with DSILI. It is not surprising that weight-loss products—specifically, certain product lines of Herbalife, Hydroxycut, and Oxy Elite Pro that may no longer be sold—feature in the highest number of published case reports related to liver injuries. These were highly successful products marketed to millions of people and so sheer volume may have contributed to the probability of adverse reactions. Some of these products were “fat burners,” defined as dietary supplements claimed to speed fat loss by increasing energy metabolism (burning calories), breaking down fat, and reducing cravings. The “burn” is claimed to be manifested by a higher body temperature and/or heart rate, both of which simulate the experience of exercise (Krishna, 2011). However, these effects may be due to stimulants and/or extracted and/or synthesized chemicals that may be harmful to the liver, heart, or other organs.

Table 5
Insufficient evidence for DS induced liver injury case reports.

Common name	Scientific name	Suggested Active compounds	Uses	Liver injury	References
Artemisinin	Isolated from <i>Artemisia annua</i>	Amodiaquine or other possible drugs combined with this herb. A partner drug with a longer half-life is used to make the derivatives more effective.	Artemisinins (artesunate, artemether, and artemisinin), have potent anti-malarial activity, and are the first line of treatment recommended by WHO against malaria (CDC, 2009). Also used against flatworms (flukes).	Severe hepatitis under prolonged amodiaquine treatment has been reported since 1985 (Guévert and Aguémon, 2009). A partner drug with a longer half-life is used to make the derivatives more effective.	CDC, 2009 Guévert and Aguémon, 2009
Bee pollen	<i>Apis mellifera</i> L.	Unknown	Immune system	33/F with elevated liver enzymes on two tablespoons of pure bee pollen for several months. Taking erythromycin for acne. 69 M with jaundice taking 14 tablets mixed herbs for 6 weeks (21 herbs, including black cohosh, chaparral, comfrey).	Shad et al., 1999
Boh-Gol-Zhee Bu Ku Zi Pa-Go-Zhee	<i>Psoralea corylifolia</i> dried mature seeds	Unknown	Asian remedy for osteoporosis, osteomalacia, and bone fractures	44/F took 10 times the usual dose for 7 weeks and experienced liver necrosis and cholestasis	Nam et al., 2005
Cascara	<i>Cascara sagrada</i>	Anthracene glycoside	Laxative	77/F Japanese with jaundice taking 3–4 capsules (250 mg <i>Cascara sagrada</i> bark + 12 other herbs) for 3 days, but also on verapamil, losartan-hydrochlorothiazide, lovastatin, and metformin.	Nakasono and Tokeshi, 2015
Chaso	Chinese herbal supplement containing <u>green tea</u> , <i>cassia toraeae semen</i> , lotus leaves, <i>Gynostemma pentaphyllum makino</i> extract, <u>aloe</u> , <i>F. crataegi fructus</i> , and raphanin semen.	Contained N-nitroso-fenfluramine, a known liver toxin (carcinogenic).	Weight loss	Six F aged 25–55 (Japanese) with elevated enzymes, 1 liver transplant	Adachi et al., 2003
Enzyte	Ginkgo biloba, Epimedium sagittum, Korean ginseng, Avenasativa extract, maca root, saw palmetto berry, Ptychopetalum olacoides (muira puama extract), octaconasol, L-arginine, Tribulus terrestris extract, pine bark, & Swedish flower pollen. Minerals such as niacin, zinc oxide, and copper	Unknown	Male enhancement	40/M with untreated hepatitis C secondary to intravenous drug use diagnosed with hepatitis.	Ramanathan et al., 2011
Ephedra or Ma Huang (Chinese name)	<i>Ephedra sinica</i>	Ephedrine and pseudoephedrine	Weight loss and energy. Has thermogenic effects. Originally a nasal decongestant and bronchial asthma treatment, but discontinued (Nadir et al., 1996). Known for cardiac side-effects (see Cardiotoxicity article)	58/F on single herb, but omeprazole drug related to hepatitis	Borum, 2001
Ephedra Note: An ephedra link to liver injury has been suggested, but it has a stronger association with cardiotoxicity (see table).				3 incidences in retrospective study of liver transplant cases 1/2001 to 10/2002, but no actual case reports: 23/F was also taking kava and died; 51/M had chronic HBV and needed a liver transplant;	Estes et al., 2003 (3)

Table 5 (continued)

Common name	Scientific name	Suggested Active compounds	Uses	Liver injury	References
Glucosamine &/or glucosamine chondroitin			Osteoarthritis	<p>21/M was also on disulfiram had a liver transplant and died.</p> <p>33/F taking Chinese herbal mixture containing Ma Huang with hepatitis. Researchers speculated that it might be another ingredient as this was the first reported case.</p> <p>12 patients with liver injuries taking dietary supplements containing other ingredients, of which two contained usnic acid Chinese herb mixture of 7 total herbs</p> <p>9 different supplements – not all 30 + ingredients listed</p> <p>71/F with underlying chronic hepatitis had elevated enzymes after taking glucosamine for 1 year. Elevated enzyme levels normalized after withdrawal.</p> <p>77/F with underlying chronic hepatitis with allergic skin reaction. Conditions may have compromised their liver's ability to metabolize drugs and DS.</p> <p>55/F (Japanese) with highly probable (CIOMS) for elevated enzymes and hepatitis. Refused to share supplements and only family revealed soybean extract, glucosamine, lutein (there may be others). The hyperferritinemia may have contributed to the liver injury.</p> <p>55/F with elevated enzymes after taking mixture of glucosamine, black cohosh, Kalms, cod liver oil, evening primrose oil for 6 months</p>	<p>Nadir et al., 1996</p> <p>Neff et al., 2004 (12 LT)</p> <p>Skoulidis et al., 2005</p> <p>Cerda et al., 2013 Cerda, 2013 Fujii et al., 2008 Smith and Dillon, 2009</p>
Hydroxycut®	See Table 2	Green tea extract; <i>Garcinia cambogia</i> (hydroxycitric acid); <i>Ma huang</i> extract (ephedra) (Bajaj et al., 2003) <i>Cissus quadrangularis</i> (toxic to animals) (Barakat et al., 1985)	Weight loss and body building	<p>44/M with pre-existing hepatitis A.</p>	Bajaj et al., 2003
See Hydroxycut® above				<p>23/M with liver failure due to hereditary coprophorphyria (HCP)</p> <p>27/M with jaundice, but also gallstones and elevated enzymes and taking other supplements: supplements (Hydroxycut, Black powder, mitotropin, xenadrine, arson, and L-glutamine powder 23)</p> <p>19/M with elevated liver enzymes, but liver biopsy revealed acute cholangitis</p>	<p>Haimowitz et al., 2015</p> <p>Kaswala et al., 2014</p> <p>Sharma et al., 2010</p>

(continued on next page)

Table 5 (continued)

Common name	Scientific name	Suggested Active compounds	Uses	Liver injury	References
Lipolyz [®] and Somalyz [®]	Fat burner Lipolyz [®] contained: Propionyl L-carnitine (500 mg), <u>green tea extract</u> (300 mg), <u>usnic acid</u> (12 mg), <u>guggulsterone</u> (10 mg)/vitamin E (20 IU), C-Amp (2 mg)	Fat burner Somalyz [®] contained: <u>GABA</u> (667 mg), Propionyl L-carnitine (167 mg), phosphatidylcholine (50 mg); <u>usnic acid</u> (4 mg), melatonin (1 mg), vitamin E (20 IU)	Weight loss	(infection of bile duct treated with antibiotics) 28/F bodybuilder with unresponsive encephalopathy requiring liver transplant after taking two fat burners for 1 month. Several of the underlined substances could have contributed. Although no cases appear with GABA, it is possible because Progabide, a GABA drug mimetic, resulted in severe hepatic failure after 4 weeks (Munoz et al., 1988).	Krishna, 2011
Mistletoe	<i>Viscum album</i> , but herbal remedy contained kelp, motherwort, <u>skullcap</u> , and mistletoe			49 yr female with hepatitis that returned 2 years later with rechallenge, but mixed herbal remedy contained skullcap, a known liver toxin.	Harvey and Colin-Jones, 1981
Move Free Advanced	Product contains <u>glucosamine</u> , <u>chondroitin</u> , hyaluronic acid, and Uniflex proprietary extract (combination of <u>Chinese skullcap</u> and black catechu).		Arthritis	2 patients with hepatotoxicity (Probable on Naranjo scale)	Linnebur et al., 2010
Multiple dietary supplements			Well being, etc	45 yr male with jaundice taking 9 different dietary supplements for 1–4 months	Cheng and Dunaway, 2010
Niacin			High blood cholesterol	16 yr male with pre-existing liver transplant (twice) had hepatitis following energy drink (3 cans within 4 h). Niacin levels unknown, but current 2015 levels at recommended daily value.	Apestequi et al., 2011
				56 yr male with emphysema admitted to hospital for difficulty breathing following a respiratory tract infection and possibly pneumonia. Taking only 1 g of niacin. Liver enzymes abnormal on 7th day in hospital, followed by liver failure and death on day 10.	Fischer, 1991
Noni	<i>Morinda citrifolia</i>	One ounce of pure noni juice daily (for several months)	Stomach cancer, improved immunity	45 yr male with elevated liver enzymes drinking unknown amount of noni juice for 3 weeks. Tested positive for hepatitis A.	Millonig et al., 2005
				38 yr F on 2 ounces daily of noni juice (% not stated, started in January). Also on phenobarbital (LiverTox.gov), and possibly on previous pain medication (not noted) following January surgery.	Mrzljak et al., 2013
Noni Notes:	West et al., (employed in the Research and Development Department of Tahitian Noni Juice, Prove, UT) questioned the causality of each noni juice case because of pre-existing medical conditions or DILI related drugs (West et al., 2006; 2007). He reported that four of the five case reports appeared in Europe around the time that noni fruit juice was approved as a Novel Food by the European-Commission in 2003 (European Commission, 2003), based on a 2002 report by the Scientific Committee on Food (European, 2002). Four of the six PubMed noni cases (67%) involved the same author, Stadlbauer, who reported these cases in Germany or Austria (Stadlbauer et al., 2005; Yuce, 2005), and the 2008 case is of			43 yr male with glioblastoma, on chemotherapy and levetiracetam (LiverTox.gov), started drinking 40 ml of noni juice for 3 weeks.	Stadlbauer et al., 2008 Stadlbauer et al., 2005

Table 5 (continued)

Common name	Scientific name	Suggested Active compounds	Uses	Liver injury	References
				questionable causality due to the presence of levetiracetam, a drug listed on LiverTox.gov as associated with liver injury (Stadlbauer et al., 2008). No PubMed cases have occurred in Hawaii, Polynesia or Asia where noni is traditionally consumed. While some commercial noni juiced products contain 100% noni juice, the majority of these products do not, and some may contain less than 10% juice that includes other juices.	
				29 yr male with previous hepatitis following paracetamol. Asthma treated with inhalative beta2-agonists and glucocorticoids. Also taking Chinese herbal mix containing bupleuri, pinellia, scutellaria (LiverTox.gov), codonopsis, glycyrrhizae, schizonepeta, and paeonia. Acute liver failure followed by liver transplant; 62yr female with acute hepatitis. Had chronic B-cell leukemia treated with fludarabine (LiverTox.gov). 14 yr boy with acute hepatotoxicity after ingesting ten 2 ounce bottles of Mind (Ultra International). Analysis revealed less than 1% noni fruit juice and no anthraquinones. Aloe vera (LiverTox.gov) was one of the ingredients.	Yu et al., 2011
				24 yr female with hepatitis. She had multiple sclerosis and was taking beta-interferon (LiverTox.gov) for 6 weeks and noni juice for 4 weeks.	Yuce et al., 2006
Onshido	Rhodiola (<i>Rhodiola rosea</i>), chaste tree (<i>Vitex agnus castus</i>), Juniper (<i>Juniperus communis</i>), soy (<i>Glycine max</i>), Asian ginseng (<i>Panax ginseng</i>), Japanese knotweed (<i>Polygonum cuspidatum</i>) extracts, brown seaweed (<i>Fucus vesiculosus</i>), dandelion (<i>Taraxacum officinale</i>), yerba mate (<i>Ilex Paraguariensis</i>), uva-ursi (<i>Arctostaphylos uva ursi</i>), phytosterols (<i>Glycine max</i>), L-theanine, caffeine, vitamins D, K, B6 and B12, folate, and calcium.	Contained N-nitrosifenfluramine, a known liver toxin (carcinogenic).	Weight loss	Six F aged 27–63 with elevated enzymes and 1 death.	Adachi et al., 2003
Red Yeast Rice	<i>Monascus purpureus</i> is the red mold that grows on rice (making it red)	Lovastatin, HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A	Lowering high blood cholesterol	62 yr female with necrosis, fibrosis and hepatitis after taking 1200 mg daily of red yeast rice for 4 months. Also on two drugs that have rare instances of liver injuries – montelukast and fluoxetine.	Roselle et al., 2008
Red Yeast Rice Notes:	It's entirely possible that the red yeast rice contributed to the liver injuries because this product the original source of Lovastatin.				
Saw Palmetto	Prostata is a combination of zinc picolinate, pyridoxine, Lalanine, glutamic acid, apis mellifica pollen, silica, hydrangea extract, panex ginseng, serenoa serrulata, and pygeum africanum.	Estrogenic and antiandrogenic effects (Jibrin et al., 2006)	Benign prostate enlargement	65 yr male with jaundice and itching after taking Prostata for two weeks. Multiple ingredients.	Hamid et al., 1997

(continued on next page)

Table 5 (continued)

Common name	Scientific name	Suggested Active compounds	Uses	Liver injury	References
	<i>Serenoa repens</i>	Excessive daily dose of 900 mg. Standard dose is 320 mg/day.		58 yr male with elevated enzymes and enlarged liver and history of Gilbert's syndrome taking high amounts of saw palmetto (900 mg of dried extract) + of berry powder (660 mg). Symptoms decreased with ceasing the supplement.	Lapi et al., 2010
	Supplement name or ingredients not provided	Unknown		55 yr male recovered alcoholic (15 yrs) with cholestatic hepatitis and acute pancreatitis. Liver may have already been compromised or influenced by pancreatitis.	Jibrin et al., 2006
SlimQuick™	24 yr female with x taking four caplets daily for 3 months. Taking tetracycline known to induce liver injury even though excluded due to histopathology.	Weinstein et al., 2012	Weight loss	52 yr female with jaundice, fulminant hepatic failure, and liver failure after drinking SlimQuick™ for two days while fasting. She was also taking metoprolol, a rare inducer of liver injury. Possible DS–drug interaction.	Whitsett et al., 2014
Vitamin A	Retinol Retinal Carotenoids	5082 IU/day consumed 5000 IU/day recommended	Vision, healthy skin and mucous membranes, reproduction, growth, and protection as an antioxidant.	46/M patient consumed Formula 1 Herbalife shake and two multivitamin tablets for 12 years. Jaundice recovery attributed to previous bile duct stricture and ceasing supplements, but a bile duct stent was inserted	Ramanathan et al., 2010
Add a DSILI case report not on the list or make comments/corrections					
New DS	New	New	New	New	New

© 2017 Amy Christine Brown. All Rights Reserved.

*These case reports are compiled from published papers in the scientific literature. Commercial formulations may have changed.

The list of possible fat burner ingredients includes caffeine, carnitine, green tea extract (EGCG), conjugated linoleic acid (CLA), garcinia cambogia (hydroxycitric acid extract claimed to inhibit ATP-citrate lyase, the enzyme response for fatty acid synthesis), forskolin (not for pregnant women; an extract from the Indian coleus plant that increases cAMP), chromium, kelp (which can negatively affect the thyroid gland), and fucoxanthin (brown seaweed pigment) (Jeukendrup and Randell, 2011). Sibutramine, an appetite suppressant, or other drugs have been found in fat burners but not on their labels, which violates FDA adulteration and labeling laws.

The most serious problem associated with fat burners or other designer dietary supplements is the recent trend to isolate a single ingredient from a plant (either by extracting or synthesizing it) and placing it in the DS without informing the FDA by submitting it as a New Dietary Ingredient (NDI) or submitting a New Drug Application (NDA). Article 1 of this series discusses this problem and the existing regulations under which this process is illegal (Brown, 2017a). An example is aegeline, a single chemical from the sacred bael plant from India that was synthesized and inserted into one of the OxyElite Pro product lines (Long, 2013). The FDA sent out Warning Letters to the manufacturers of OxyElite Pro, along with other fat burners such as certain green tea extract-containing products, Hydroxycut, and LipoKinetix.

Illegal sale of medications as DS remains a concern. For instance, the FDA recalled Aktive High Performance Fat Burner Gold because it was adulterated with the drugs sibutramine, desmethylsibutramine, and phenolphthalein.

11.2.2. Withdrawal of hepatotoxic products

As a result of FDA actions and/or other factors, approximately 35% (9/26) of the DS related to liver toxicity in these tables are no longer sold. These include anabolic steroids, Flavocoxid, Hydroxycut® (earlier version), LipoKinetix®, OxyElite Pro®, Sen-nomotokounou, Venencapsan®, Venoplant, and usnic acid (highlighted in gray in Tables 3 and 4). It is possible that many of the listed dietary supplements now have different formulations and no longer contain the suspect ingredient(s). Only one product listed in the DS Toxic Tables was still sold on the Internet, and that was usnic acid, but it consisted of a liquid extract of an undisclosed concentration.

12. A balanced perspective

This review reveals that over the past 50 years, only approximately 21 herbs (minus germander and usnic acid) and 12 DS (minus the nine no longer sold) posed a possible risk for liver injuries in certain individuals. Vitamin A and niacin were on the list due to excessive intake (a disqualifying criteria), and it should not

be forgotten that these are known liver toxins at high doses. The list would be slightly longer if Chinese herbs were included, but this was a difficult task given that these remedies traditionally do not consist of just one herb, and many of the relevant case reports may be published in other languages. Nevertheless, these case reports can be added to the online DS Toxic Tables in the future.

In summary, making the following corrections to the calculations determining the DS contribution to liver injuries in previous articles would yield a more balanced perspective:

- 1) Liver injury prevalence is unknown. There is no annual incident count collected by one government or non-profit agency from clinicians and hospital liver centers. As such, the prevalences of DILI and DSILI obtained from DILIN were not derived from a population-based study (Vuppalanchi et al., 2015). Most research is either retrospective or prospective, often based at selected clinical settings over a selected time period, often with an arbitrary number of subjects. As a result, no two prevalence studies are similar and therefore making comparisons between studies and for different time periods (years) is difficult.
- 2) Liver injuries are rare. The prevalence for DILI is so low that these injuries are classified as rare. In comparison, the prevalence for DSILI is lower and even rarer. Drugs far outnumber DS for liver injury causes and the most commonly responsible drugs are antibiotics, anti-epileptics, and non-steroidal anti-inflammatory drugs (NSAIDs). Over 1100 classical drugs (estimates vary widely) are potentially hepatotoxic (Larrey and Pageaux, 2005), but only approximately 12 currently sold DS products have documented hepatotoxicity cases based on this review. Nine additional DS are no longer sold in the United States. More specifically, The Physicians' Desk Reference (PDR, 2016) listed 370 drugs possibly causing hepatic abnormalities, 124 drugs contraindicated in people with liver disease, and 90 drugs labeled as possible causes of acute liver failure (Kaplowitz,

2004). Many of these drugs remain on the market despite liver injury potential with the expectation that the physician will conduct liver enzyme tests. One example is methotrexate, used for over 50 years; it can improve psoriasis symptoms in 60% of patients, but 33% experience liver injuries that may simply include elevated enzymes (Barker et al., 2011). Tyrosine kinase inhibitors (TKIs) were found related to increased ALT, AST (Iacovelli et al., 2014).

- 3) Current DSILI estimates appear inaccurate. Improved scientific accuracy of DSILI statistics would be achieved by:
 - a) Adding DS categories. A recent publication stated that "... among DILI cases, DS are the second most common cause" (Chalasanani et al., 2014), but this ranking was determined by dividing the 609 drugs studied into nine categories while combining all 145 DS into a single category for comparison (Chalasanani, 2015). The DILIN actually created 13 categories for DS, but these categories were not used when reporting that DS were the "second most common cause" of liver injuries (Vuppalanchi et al., 2015).
 - b) Removing illegal anabolic steroids or other ingredients masquerading as DS from valid DSILI statistical calculations. These products are illegal and already regulated by the FDA or other regulatory agencies (McGuffin, 2013).
 - c) Including acetaminophen. APAP, the number one cause of acute liver failure and responsible for about 1000 of the approximately 2000 annual cases of acute liver failure, is frequently excluded when evaluating the impact of drugs responsible for DILI. This unfairly lowers the total number of drugs, while simultaneously inflating the proportion of liver injuries caused by DS. One solution is to exclude only APAP cases due to self-harm, as that is a misuse of the drug.
 - d) Including all causes of liver injuries. Comparing DSILI to the total number of liver injuries from ALL causes provides an accurate perspective of the total number of liver injuries due




Fig. 1. Etiology of acute liver failure in USA (FDA-a, 2015).

Table 6
Comparing yearly liver transplants and deaths due to drugs and DS.

Author	Liver transplant (drugs)	Death (drugs)		Liver transplant (DS)	Death (DS)
Andrade et al., 2005	0.5	1	vs	1	0
Chalasanani, 2008	4	7	vs	0.3	0
Fontana et al., 2014	3.1	1.3	vs	1.1	0.14
Average	2.4	3.1	vs	0.8	0.05

to DS. The data become unfairly skewed when comparing liver injuries from drugs and DS to their combined totals. For instance, all the other causes of liver transplant listed in Table 2 should be included, along with etiologies for acute liver failure such as undetermined; hepatitis A, B, or C; autoimmunity; ischemia; Wilson's; Budd-Chiari; pregnancy, and other (see Fig. 1).

- e) Naming the specific DS products related to liver injuries. Not disclosing the DS related to liver injuries calls into question any statistical conclusions because the reported proportion of DSILI cases cannot be challenged (e.g., how many were illegal steroid drugs?). Unfortunately, such conclusions are often accepted and repeatedly cited in subsequent studies without scientific scrutiny.
- 4) The vast majority of serious liver injuries are unrelated to DILI or DSILI. Liver transplant and death are the most serious outcomes of liver injuries; fortunately, only a very small percentage of people experience them. Neither drugs nor DS are primarily responsible. Table 6 shows that the incidences of liver transplant and death resulting from drug use averaged from three major studies equal only 2.4 and 3.1 cases annually, respectively; barely 1 liver transplant and no deaths annually result from DS use. That totals to approximately 5.5 per year for drugs, 1 per year for DS. Omitting the cases due to illegal drugs (approximately 24%) reduces the number of annual cases due to DS by one fourth (0.85 minus 0.20), to equal 0.65 per year. More importantly, these extremely low values for both drugs and DS would become close to zero if all causes of liver injury, such as hepatitis C, were included in the calculations. The U.S. media's emphasis on these "rising" numbers of DSILI cases (less than 1 death a year) is disproportionate given that hepatitis C infection resulted in 1800 liver transplants (Table 2) and 19,368 deaths in 2013 (CDC, 2015).

When scientific accuracy is improved through these statistical corrections, DSILI become significantly less frequent than previously reported or portrayed. The overall picture is that most people recover from DILI and DSILI, although a very small minority experience chronic liver disease, liver failure, liver transplant, and/or death. Table 6 reveals the reality that very few people either receive liver transplants or die due to DS-related hepatotoxicity. As such, it appears the "dangers" of DS have been inflated in the media, and need to be normalized for scientific accuracy. In this balanced perspective, the existing DS that do pose a hepatotoxic risk to the public should be marked with warning labels (as drugs are) and/or removed from the shelf by existing regulatory authorities, especially if they are illegal and/or fraudulent products.

13. Current regulations

The FDA, Federal Trade Commission, Attorneys General Office, and Department of Justice work to protect the public from DS-related liver injuries (Brown, 2017a). As a result, almost one third of the DS in this review table are no longer sold (indicated by shaded DS in Tables 3 and 4).

Clustered cases should, but sometimes do not, receive immediate attention. Before calling for stricter DS regulations, however, one should consider the likely effectiveness of this approach. If stringent FDA regulations cannot prevent the 1,000 annual DILI from occurring, then why apply the same regulations to DS when the vast majority are not liver toxic and any potential hazards affect only the 10% or less of the population consuming non-vitamin/mineral DS? If over 1,000 drugs are potentially hepatotoxic (compared to approximately 21 herbs and 12 DS according to this review), and these drugs have not been removed from the market for potential hepatotoxicity, then why is a stricter standard being applied to the dietary supplement industry? In fact, 21 DS represent only 0.02% of the average number of drugs that can be problematic to the liver.

Although rare, DSILI do occur, and must be immediately intercepted by government agencies. The real solution is to fully and consistently enforce existing laws and regulations. Historically, inconsistent enforcement has allowed a few companies to cross the legal line without any consequences. Article one of this series addresses this issue. Despite the often repeated theme that "regulation is not rigorous enough to assure complete safety of DS products," the fact is that "enforcement" has not been sufficiently rigorous. The recent media emphasis placed on "regulation" appears to be another attempt to support legislative changes, but regulations are already in place and simply need to be "enforced."

14. Limitations

The "DS Toxic Tables" in this review series are based on the PubMed indexing of peer-reviewed scientific journal articles and while comprehensive, are not entirely inclusive of all the literature, nor should it be viewed as such. Limiting the literature review to this resource ensures some degree of standardization. This review did not cover literature indexing resources of other countries or regions that may have more varied histories or usage of DS (including herbs) as part of their traditional treatments – for example, India (Ayurvedic), China (Traditional Chinese Medicine), Japan (Kampo or Kampo), Polynesia, Africa, and South America, and others. Regional plant names and uses may be different and not identified with those commonly recognized in the United States or reported in PubMed. In addition, this review did not include non-peer reviewed, but possibly more plethoric reports integrated through international toxicity lists, MedWatch, NapAlert, Poison Control Centers, MedWatch, World Health Organization (WHO), commercial entities, and other agencies. The Institute of Medicine recommended that the FDA work with the nation's poison control centers as a source of adverse event reports, but the reliability of date is limited by factors such as inaccurate coding, co-medications, incomplete product information, lack of laboratory testing, and inadequate follow-up (Haller, 2008). Incompleteness is also a limiting factor for the tables presented here as not all case reports may be included. Other case report limitations are discussed in Article 1 of this series (Brown, 2017a).

Further limiting the results were the exclusion criteria of case reports involving herb combinations (some exceptions), Chinese

herb mixtures, teas of mixed herb contents, mushrooms, poisonous plants, self-harm, excess dose (except vitamins/minerals), drugs or illegal drugs, drug–herb interactions, and confounders of drugs or diseases.

Drug-herb or herb–herb interactions can occur because some herbs act as substrates for cytochrome P450s (CYPs) and/or P-glycoprotein leading to altered drug clearance, response, and toxicity (Yang et al., 2006). The majority of drug–herb interactions were not severe (Posadzki et al., 2013), and extensively covered in other reviews (Hu et al., 2005; Posadzki et al., 2013; Yang et al., 2006). Drug-herb interactions are important to consider for the approximately one third (34.3%) of all US adults reporting concomitant DS and prescription medication use (Farina et al., 2014). It has been recommended that patients on immunosuppressant drugs, and especially transplant recipients, avoid herbs such as St. John's wort and others (chamomile, Earl grey teas, etc.) that can reduce cyclosporine levels (Rahimi and Abdollahi, 2012; Nowack and Nowak, 2005). In addition, the American Society of Anesthesiologists recommends discontinuation of herbal medicines two or more weeks prior to surgery (Dasgupta and Bernard, 2006).

The most common adulterant in DS is drugs that are either added by a deliberate criminal act or through accidental contamination by uncleaned manufacturing equipment. Article one of this series addresses adulterated products defined by the FDA as “tainted products marketed as DS” (Brown, 2017a). Regardless of their source, toxicities are often under-reported, so published case reports may signal an emerging problem. Underreporting to regulatory authorities and publication in peer-reviewed journals is a repeating theme for case reports, especially in developing countries (Neergheen-Bhujun, 2013). Other reviews on DSILI have been published (Bunchorntavakul, 2013; Chitturi and Farrell, 2008; Larrey, 1997; Licatta, 2013; Navarro and Lucena, 2014; Navarro et al., 2013, 2014; O'hara et al., 1998; Pittler and Ernst, 2003; Posadzki et al., 2013; Rohilla et al., 2016; Schiano, 2003; Seeff et al., 2015; Stickel and Shouval, 2015; Stickel et al., 2011, 2005; Teschke, 2014; Teschke et al., 2012; Zheng and Navarro, 2015), but the current table attempts to cite all case reports in a tabular form, does not include reviews, restricts confounding variables, and can be continuously updated online.

15. Additional case reports

The case reports presented here do not reflect all the case reports in the literature, so additional case report submissions, pre-existing or new, are welcomed online. The author is available to assist in writing up case reports for publication, after which the data will be added to the (<http://mscr.hawaii.edu/faculty/amybrown/>) online table.

16. DS Toxic tables for proactive protection

These continuously updated online DS Toxic Tables can now be accessed by consumers, clinicians, and corporations to find DS and/or their ingredients that have been reported to be related to toxicity. If a DS is related to toxicity cases, regardless of how small due to idiosyncratic DS reactions, then why impart the risk to the consumer or corporation? The DS ingredients listed in these tables may need further consideration by government agencies, DS companies, manufacturers, distributors, and formulators.

The safest route for consumers is to avoid these potentially toxic DS. As always, until more information is available, it appears that DS consumption may not be prudent for people with liver, kidney, heart, and/or cancer conditions, organ transplant recipients, two weeks prior to surgery, pregnancy (except prenatal vitamins and minerals), lactation, concomitant medication, underlying disease

with the exception of standard dietary therapies, and/or medical treatment without a physician's approval.

These online DS Toxic Tables and accompanying case reporting form will help provide continued Phase IV post marketing surveillance to detect possible DS toxicity cases (FDA-d, 2014). Perhaps this will help alert the government agencies responsible for upholding existing laws regulating DS, so that future outbreaks can be curtailed or even prevented.

17. Bullet summary

Herbs

- Approximately 21 herbs have been related to liver injury case reports (1966–July, 2016). Germander and usnic acid are no longer sold in the United States.
- The next three most prominent offenders (black cohosh, kava, and green tea extracts) may need warning labels.
 - USP accepts black cohosh into USP Compendia Category A, but with labeled warnings. Discontinue use with symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice.
 - USP did not admit kava into USP-NF monograph development process due to possible liver injury.
 - USP did not admit *Phyllanthus amarus* extract (whole herb in Class A) or natto extract (vitamin K content may interfere with blood thinners).
- The last three, chaparral, aloe vera, and greater celandine, had infrequent liver injury reports over the last 50 years, but may still need warning labels.
- The remaining herbs have far fewer publications, but that does not negate their possible implications in liver toxicity — especially fo-ti, pennyroyal, senna, skullcap, and valerian.
- Traditional Chinese Medicine herbal medicinals appear to have a higher HILI rate, suggesting a greater need to review them for related liver injuries.
- Patients taking immunosuppressant drugs, and especially transplant recipients, should avoid herbs such as St. John's wort and others (chamomile, Earl grey teas, etc.) that can reduce cyclosporine levels.
- The American Society of Anesthesiologists recommends discontinuation of herbal medicines two or more weeks prior to surgery.

17.1. Dietary supplements

- Approximately 12 DS in the literature have been related to liver injury case reports (1966–June, 2016). Approximately 35% (9/26) of the DS related to liver toxicity in these tables are no longer sold. Vitamin A and niacin were on the list, but were not counted as they are due to excess intake.
- DS sold for bodybuilding and weight loss, especially “fat burners,” are most commonly associated with DSILI. Anabolic steroids are illegal and not DS.
- The most serious problem associated with fat burners or other designer dietary supplements is the recent trend to isolate a single ingredient from a plant (either by extracting or synthesizing it) and placing it in the DS without informing the FDA by submitting a New Dietary Ingredient (NDI) or submitting a New Drug Application (NDA).
- The names, ingredients, and corporations of DS can change so those listed here may not reflect current products on the market.

17.2. Balanced perspective

- DILI are rare, and DSILI are even more rare.
- Current DSILI estimates in the literature should be corrected by:
 1. Removing anabolic steroids and other drugs/NDI from DSILI calculations.
 2. Including acetaminophen, the number one cause of acute liver failure, and all other causes of liver injuries for valid DSILI estimations.
 3. Listing the DS related to liver injuries (as done for drugs).
 4. Balancing perspective by reporting the annual liver transplant and death resulting from drug use that averages 2.4 and 3.1 cases respectively, compared to about only 1 liver transplant and zero deaths annually from DS (2014).
 5. Realizing that the U.S. media's emphasis on "rising" numbers of DSILI cases is disproportionate to the facts.
- DS that do pose a hepatotoxic risk should be marked with warning labels (as drugs are) and/or removed from the shelf by existing regulatory authorities, especially if they are illegal and/or fraudulent products ("tainted products marketed as DS").

Conflict of interest/Caveat

Amy Brown is CEO of Natural Remedy Labs, LLC, and has served as an expert witness in herb and DS cases. The names, formulations and corporate name and/or ownership of DS may change, so any identification in this publication may no longer apply.

Transparency document

Transparency document related to this article can be found online at <http://dx.doi.org/10.1016/j.fct.2016.07.001>.

References

- Abu el, Wafa Y., Benavente, Fernández A., Talavera, Fabuel A., Pérez, Ramos MA., Ramos-Clemente, J.I., 2005. Acute hepatitis induced by *Camellia sinensis* (green tea). *An Med Interna* 22 (6), 298 [Article in Spanish].
- Adachi, M., Saito, H., Kobayashi, H., Horie, Y., Kato, S., Yoshioka, M., Ishii, H., 2003. Hepatic injury in 12 patients taking the herbal weight loss AIDS Chaso or Onshido. *Ann Intern Med* 139 (6), 488–492.
- Alderman, S., Kailas, S., Goldfarb, S., Singaram, C., et al., 1994. Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy. *Am. J. Gastroenterol.* 19 (3), 242–247.
- Anderson, I.B., Mullen, W.H., Meeker, J.E., Khojasteh-Bakht, S.C., Oishi, S., Nelson, S.D., Blanc, P.D., 1996. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. *Ann. Intern Med.* 124 (8), 726–734.
- Andrade, R.J., Lucena, M.I., Fernández, M.C., Pelaez, G., Pachkoria, K., García-Ruiz, E., García-Muñoz, B., González-Grande, R., Pizarro, A., Durán, J.A., Jiménez, M., Rodrigo, L., Romero-Gomez, M., Navarro, J.M., Planas, R., Costa, J., Borrás, A., Soler, A., Salmerón, J., Martín-Vivaldi, R., 2005. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology* 129 (2), 512–521.
- Andrade, R.J., López-Ortega, S., López-Vega, M.C., Robles, M., Cueto, I., Lucena, M.I., 2008. Idiosyncratic drug hepatotoxicity: a 2008 update. *Expert Rev. Clin. Pharmacol.* 1 (2), 261–276.
- Apestegui, C.A., Julliard, O., Ciccarelli, O., et al., 2011. Energy drinks: another red flag for the liver allograft. *Liver Transpl.* 17, 1117–1118.
- Appelhans, K., Smith, C., Bejar, E., Henig, Y.S., 2011. Revisiting acute liver injury associated with herbalife products. *World J. Hepatol.* 3 (10), 275–277.
- Araujo, J.L., Worman, H.J., 2015. Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. *BMJ Case Rep.* 2015.
- Au, J.S., Navarro, V.J., Rossi, S., 2011. Review article: drug-induced liver injury—its pathophysiology and evolving diagnostic tools. *Aliment. Pharmacol. Ther.* 34 (1), 11–20.
- Bach, N., Thung, S.N., Schaffner, F., 1989. Comfrey herb tea-induced hepatic veno-occlusive disease. *Am. J. Med.* 87 (1), 97–99.
- Bajaj, J., Knox, J.F., Komorowski, R., Saeian, K., 2003. The irony of herbal hepatitis. Ma-huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. *Dig. Dis. Sci.* 48 (10), 1925–1928.
- Barakat, S.E., Adam, S.E., Maglad, M.A., Wasfi, I.A., 1985. Effects of *Cissus quadrangularis* on goats and sheep in Sudan. *Rev. Elev. Med. Vet. Pays Trop.* 38 (2), 185–194.
- Barker, J., Horn, E.J., Lebwohl, M., Warren, R.B., Nast, A., Rosenberg, W., Smith, C., 2011. International Psoriasis Council. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. *J. Eur. Acad. Derm. Venereol.* 25 (7), 758–764.
- Bakerink, J.A., Gospe Jr., S.M., Dimand, R.J., Eldridge, M.W., 1996. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. *Pediatrics* 98 (5), 944–947.
- Banarova, A., Koller, T., Payer, J., 2012. Toxic hepatitis induced by *Polygonum multiflorum*. *Vnitr Lek.* 58 (12), 958–962 [Article in Slovak].
- Bassan, M., 2012. A case for immediate-release niacin. *Heart Lung* 41 (1), 95–98.
- Batchelor, W.B., Heathcote, J., Wanless, I.R., 1995. Chaparral-induced hepatic injury. *Am. J. Gastroenterol.* 90 (5), 831–833.
- Belfrage, B., Malmström, R., 2008. Several cases of liver affected by aloe vera. *Lakartidningen* 105 (1–2), 45 [Article in Swedish].
- Bonkovsky, H.L., 2006. Hepatotoxicity associated with supplements containing Chinese green tea (*Camellia sinensis*). *Ann. Intern Med.* 144 (1), 68–71.
- Benninger, J., Schneider, H.T., Schuppan, D., Kirchner, T., et al., 1999. Acute hepatitis induced by greater celandine (*Chelidonium majus*). *Gastroenterology* 117 (5), 1234–1237.
- Ben Yahia, M., Mavie, P., Métreau, J.M., Zafrani, E.S., Fabre, M., Gatineau-Saillant, G., Dhumeaux, D., Mallat, A., 1993. Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases. *Gastroenterol. Clin. Biol.* 17 (12), 959–962 [Article in French].
- Beuers, U., Spengler, U., Pape, G.R., 1991. Hepatitis after chronic abuse of senna. *Lancet* 337, 372–373.
- Bilal, M., Patel, Y., Burkitt, M., Babich, M., 2015. Linoleic acid induced acute hepatitis: a case report and review of the literature. *Case Rep. Hepatol.* 2015, 807354.
- Björnsson, E.S., Bergmann, O.M., Björnsson, H.K., Kvarn, R.B., Olafsson, S., 2013. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology* 144 (7), 1419–25, 1425.e1–3; quiz e19–20.
- Borum, M.L., 2001. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. *Am. J. Gastroenterol.* 96 (5), 1654–1655.
- Bottenberg, M.M., Wall, G.C., Harvey, R.L., Habib, S., 2007. Oral aloe vera-induced hepatitis. *Ann. Pharmacother.* 41 (10), 1740–1743.
- Brauer, R.B., Stangl, M., Stewart, J.R., Pfab, R., Becker, K., 2003. Acute liver failure after administration of herbal tranquilizer kava-kava (*Piper methysticum*). *J. Clin. Psychiatry* 64, 216–218.
- Brent, J., 1999. Three new herbal hepatotoxic syndromes. *J. Toxicol. Clin. Toxicol.* 37 (6), 715–719.
- Brown, A.C., 2017a. An overview of herb and dietary supplement efficacy, safety, and regulations in the United States with suggested improvements. Part 1 of 5 Series. *Food Chem Toxicol.* 107, 449–471.
- Brown, A.C., 2017b. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series. *Food Chem Toxicol.* 107, 472–501.
- Brown, A.C., 2017c. Kidney toxicity related to herbs and dietary supplements: online table of case reports. Part 3 of 5 series. *Food Chem Toxicol.* 107, 502–519.
- Brown, A.C., 2017a. Heart toxicity related to herbs and dietary supplements: online table of case reports. Part 4 of 5 series. *Food Chem Toxicol.* (in press).
- Brown, A.C., 2017b. Cancer related to herbs and dietary supplements: online table of case reports. Part 5 of 5 series. *Food Chem Toxicol.* (in press).
- Bunchorntavakul, C., Reddy, K.R., 2013. Review article: herbal and dietary supplement hepatotoxicity. *Aliment. Pharmacol. Ther.* 37 (1), 3–17.
- Bujanda, L., Palacios, A., Sil varino, R., Sanchez, A., Munoz, C., 2002. Kava-induced acute icteric hepatitis. *Gastroenterol. Hepatol.* 25, 434–435.
- Campbell, T.C., Hayes, J.R., 1974. Role of nutrition in the drug-metabolizing enzyme system. *Pharmacol. Rev.* 26 (3), 171–197.
- Caravaca-Magarios, F., Cubero-Gomez, J.J., Arroboscava, M., 1985. Renal and hepatic injuries in human intoxication with *Atractylis gummifera*. *Nefrologia* 5, 205–201.
- Carey, E.J., Vargas, H.E., Douglas, D.D., Balan, V., Byrne, T.J., Harrison, M.E., Rakela, J., 2008. Inpatient admissions for drug-induced liver injury: results from a single center. *Dig. Dis. Sci.* 53 (7), 1977–1982.
- Castaña, G., Etchart, C., Sookoian, S., 2006. Vitamin A toxicity in a physical culturist patient: a case report and review of the literature. *Ann. Hepatol.* 5 (4), 293–295.
- Castot, A., Larrey, D., 1992. Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance. *Gastroenterol. Clin. Biol.* 16 (12), 916–922 [French].
- Catanzano, G., Delons, S., Benyahia, T.D., 1969. 2 cases of poisoning due to "gum thistle" (*Atractylis gummifera* L.). Clinical development and anatomic-pathologic lesions. *Maroc. Med.* 49 (529), 651–655 [Article in French].
- CDC (Centers of Disease Control & Prevention), 1992. Chaparral-induced toxic hepatitis—California and Texas, 1992. *MMWR Morb. Mortal. Wkly. Rep.* 41 (43), 812–814.
- CDC, 2013. Chronic liver disease and cirrhosis. <https://www.cdc.gov/nchs/fastats/liver-disease.htm>.
- CDC, 2002. Hepatic toxicity possibly associated with kava-containing products—United States, Germany, and Switzerland, 1999–2002. *MMWR Morb. Mortal. Wkly. Rep.* 51 (47), 1065–1067.
- CDC, 2009. Hepatitis temporally associated with an herbal supplement containing artemisinin - Washington, 2008. *MMWR Morb. Mortal. Wkly. Rep.* 58 (31), 854–856.

- Cerda, C., Burguera, M., Pares, A., 2013. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. *World J. Gastroenterol.* 19 (32), 5381–5384.
- Chalasanani, N., Björnsson, E., 2010. Risk factors for idiosyncratic drug-induced liver injury. *Gastroenterology* 138 (7), 2246–2259.
- Chalasanani, N., Bonkovsky, H.L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K.R., Watkins, P.B., Navarro, V., Barnhart, H., Gu, J., Serrano, J., 2015. United States drug induced liver injury network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. *Gastroenterology* 148 (7), 1340–52.e7.
- Chalasanani, N., Fontana, R.J., Bonkovsky, H.L., Watkins, P.B., Davern, T., Serrano, J., Yang, H., Rochon, J., 2008. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. *Gastroenterology* 135 (6), 1924–34, 1934.
- Chalasanani, N.P., Hayashi, P.H., Bonkovsky, H.L., Navarro, V.J., Lee, W.M., Fontana, R.J., 2014. Practice parameters committee of the American College of Gastroenterology. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. *Am. J. Gastroenterol.* 109 (7), 950–66; quiz 967.
- Chalasanani, N., Vuppalanchi, R., Navarro, V., Fontana, R., Bonkovsky, H., Barnhart, H., Kleiner, D.E., Hoofnagle, J.H., 2012. Acute liver injury due to flavocoxid (Lim-brel), a medical food for osteoarthritis: a case series. *Ann. Intern. Med.* 156 (12), 857–60, W297–300.
- Chao, S., Anders, M., Turbay, M., Olaiz, E., Mc Cormack, L., Mastai, R., 2008. [Toxic hepatitis by consumption Herbalife products a case report]. [Article Span. *Acta Gastroenterol Latinoam* 38 (4), 274–277.
- Chen, G.C., Ramanathan, V.S., Law, D., Funchain, P., Chen, G.C., French, S., Shlopov, B., Eysselein, V., Chung, D., Reicher, S., Pham, B.V., 2010. Acute liver injury induced by weight-loss herbal supplements. *World J. Hepatol.* 2 (11), 410–415.
- Chen, M., Borlak, J., Tong, W., 2013. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. *Hepatology* 58 (1), 388–396.
- Cheng, F.K., Dunaway, P., 2010. A case of supplement-induced hepatotoxicity. *Case Rep. Med.* 2010 pii: 262706.
- Cheruvattath, R., Orrego, M., Gautam, M., Byrne, T., Alam, S., Voltchenok, M., Edwin, M., Wilkens, J., Williams, J.W., Vargas, H.E., 2006. Vitamin A toxicity: when one a day doesn't keep the doctor away. *Liver Transpl.* 12 (12), 1888–1891.
- Chitturi, S., Farrell, G.C., 2008. Hepatotoxic slimming aids and other herbal hepatotoxins. *J. Gastroenterol. Hepatol.* 23 (3), 366–373.
- Chiu, Y.K., Lai, M.S., Ho, J.C., Chen, J.B., 1999. Acute fish liver intoxication: report of three cases. *Chang. Yi Xue Za Zhi* 22 (3), 468–473.
- Chojkier, M., 2003. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. *J. Hepatol.* 39 (3), 437–446.
- Chow, E.C., Teo, M., Ring, J.A., Chen, J.W., 2008. Liver failure associated with the use of black cohosh for menopausal symptoms. *Med. J. Aust.* 188 (7), 420–422.
- Christl, S.U., Seifert, A., Seeler, D., 2009. Toxic hepatitis after consumption of traditional kava preparation. *J. Travel Med.* 16 (1), 55–56.
- Church, R.J., Gatti, D.M., Urban, T.J., Long, N., Yang, X., Shi, Q., Eaddy, J.S., Mosedale, M., Ballard, S., Churchill, G.A., Navarro, V., Watkins, P.B., Threadgill, D.W., Harrill, A.H., 2015. Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. *Food Chem. Toxicol.* 76, 19–26.
- Cohen, D.L., Del Toro, Y., 2008. A case of valerian-associated hepatotoxicity. *J. Clin. Gastroenterol.* 42 (8), 961–962.
- Cohen, S.M., O'Connor, A.M., Hart, J., Merel, N.H., Te, H.S., 2004. Autoimmune hepatitis associated with the use of black cohosh: a case study. *Menopause* 11 (5), 575–577.
- Cooke, C., Carr, I., Abrams, K., Mayberry, J., 2000. Arrowroot as a treatment for diarrhoea in irritable bowel syndrome patients: a pilot study. *Arq. Gastroenterol.* 37 (1), 20–24.
- Crijns, A.P., de Smet, P.A., van den Heuvel, M., Schot, B.W., Haagsma, E.B., 2002. Acute hepatitis after use of a herbal preparation with greater celandine (*Che-lidonium majus*). *Ned. Tijdschr. Geneesk.* 146 (3), 124–128 [Article in Dutch].
- Curciarello, J., De Ortúzar, S., Borzi, S., Bosia, D., 2008. Severe acute hepatitis associated with intake of Aloe vera tea. *Gastroenterol. Hepatol.* 31, 436–438 [Article in Spanish].
- Dantuluri, S., North-Lewis, P., Karthik, S.V., 2011. Gotu Kola induced hepatotoxicity in a child - need for caution with alternative remedies. *Dig. Liver Dis.* 43 (6), 500.
- Dara, L., Hewett, J., Lim, J.K., 2008. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. *World J. Gastroenterol.* 14 (45), 6999–7004.
- Dasgupta, A., Bernard, D.W., 2006. Herbal remedies: effects on clinical laboratory tests. *Arch. Pathol. Lab. Med.* 130 (4), 521–528.
- Davis, D.C., Potter, W.Z., Jollow, D.J., Mitchell, J.R., 1974. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. *Life Sci.* 14 (11), 2099–2109.
- Dao, T., Peytier, A., Galateau, F., Vaila, A., 1993. Chronic cirrhotic hepatitis induced by germander. *Gastroenterol. Clin. Biol.* 17 (8–9), 609–610 [Article in French].
- De Smet, P.A., Van den Eertwegh, A.J., Lesterhuis, W., Stricker, B.H., 1996. Hepatotoxicity associated with herbal tablets. *BMJ* 313 (7049), 92.
- Diaz, D., Ferroudji, S., Heran, B., Barneon, G., Larrey, D., Michel, H., 1992. Fulminant hepatitis caused by wild germander. *Gastroenterol. Clin. Biol.* 16 (12), 1006–1007 [Article in French].
- Dong, H., Slain, D., Cheng, J., Ma, W., Liang, W., 2014. Eighteen cases of liver injury following ingestion of *Polygonum multiflorum*. *Complement. Ther. Med.* 22 (1), 70–74.
- Dourakis, S.P., Papanikolaou, I.S., Tzemanakis, E.N., Hadziyannis, S.J., 2002. Acute hepatitis associated with herb (*Teucrium capitatum* L.) administration. *Eur. J. Gastroenterol. Hepatol.* 14 (6), 693–695.
- Duque, J.M., Ferreira, J., Salgueiro, E., Manso, G., 2007. Hepatotoxicity associated with the consumption of herbal slimming products. *Med. Clin. Barc.* 128 (6), 238–239 [Article in Spanish].
- Durazo, F.A., Lassman, C., Han, S.H., Saab, S., Lee, N.P., Kawano, M., Saggi, B., Gordon, S., Farmer, D.G., Yersiz, H., Goldstein, R.L., Ghoobrial, M., Busuttill, R.W., 2004. Fulminant liver failure due to usnic acid for weight loss. *Am. J. Gastroenterol.* 99 (5), 950–952.
- Ebrahim, V., Albeldawi, M., Chiang, D.J., 2012. Acute liver injury associated with glucosamine dietary supplement. *BMJ Case Rep.* 2012.
- Elinav, E., Pinsky, G., Safadi, R., Pappo, O., Bromberg, M., Anis, E., Keinan-Boker, L., Broide, E., Ackerman, Z., Kaluski, D.N., Lev, B., Shouval, D., 2007. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. *J. Hepatol.* 47 (4), 514–520.
- Ellsworth, M.A., Anderson, K.R., Hall, D.J., Freese, D.K., Lloyd, R.M., 2014. Acute liver failure secondary to niacin toxicity. *Case Rep. Pediatr.* 2014, 692530.
- Enbom, E.T., Le, M.D., Oesterich, L., Rutgers, J., French, S.W., 2014. Mechanism of hepatotoxicity due to black cohosh (*Cimicifuga racemosa*): histological, immunohistochemical and electron microscopy analysis of two liver biopsies with clinical correlation. *Exp. Mol. Pathol.* 96 (3), 279–283.
- Escher, M., Desmeules, J., Giostra, E., Menta, G., 2001. Hepatitis associated with Kava, a herbal remedy for anxiety. *BMJ* 322 (7279), 139.
- Estes, J.D., Stolpman, D., Olyaei, A., Corless, C.L., Ham, J.M., Schwartz, J.M., Orloff, S.L., 2003. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. *Arch. Surg.* 138 (8), 852–858.
- European Commission, Commission Decisions of 5 June 2003 authorizing the placing on the market of “noni juice” (juice of the fruit of *Morinda citrifolia* L.) as a novel food ingredient under Regulation (EC) Nr. 258/97 of the European Parliament and of the Council. *Official Journal of the European Union* 2003; L 144/12:12.6.2003.
- European Commission on Health and Consumer Protection Directorate-General, 2002. Opinion of the Scientific Committee on Food on Tahitian Noni Juice. Available at: http://ec.europa.eu/food/fs/sc/scf/out151_en.pdf.
- Farina, E.K., Austin, K.G., Lieberman, H.R., 2014. Concomitant dietary supplement and prescription medication use is prevalent among US adults with doctor-informed medical conditions. *J. Acad. Nutr. Diet.* 114 (11), 1784–90.e2.
- Favreau, J.T., Ryu, M.L., Braunstein, G., Orshansky, G., Park, S.S., Coody, G.L., Love, L.A., Fong, T.L., 2002. Severe hepatotoxicity associated with the dietary supplement Lipokinex. *Ann. Intern. Med.* 136 (8), 590–595.
- FDA-a, 08/05/2015. Drug-induced Liver Toxicity. <http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm071471.htm> (accessed 15.12.15.).
- FDA-b, 2009. Guidance for Industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation. US Department of Health and Human Services, FDA, CDER, CBER.
- FDA-c, 08/16/2013. Lipokinex. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm172824.htm> (accessed 01.12.15.).
- FDA-d, 2014. Postmarketing Surveillance Programs. FDA. <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm090385.htm> (accessed 06.26.16.).
- Federico, A., Tiso, A., Loguercio, C., 2007. A case of hepatotoxicity caused by green tea. *Free Radic. Biol. Med.* 43 (3), 474.
- Fernández, J., Navascués, C., Albines, G., Franco, L., Pipa, M., Rodríguez, M., 2014. Three cases of liver toxicity with a dietary supplement intended to stop hair loss. *Rev. Esp. Enferm. Dig.* 106 (8), 552–555.
- Ferrucci, L.M., Bell, B.P., Dhotre, K.B., Manos, M.M., Terrault, N.A., Zaman, A., Murphy, R.C., Vanness, G.R., Thomas, A.R., Bialek, S.R., Desai, M.M., Sofair, A.N., 2010. Complementary and alternative medicine use in chronic liver disease patients. *J. Clin. Gastroenterol.* 44 (2), e40–e45.
- Fischer, D.J., Knight, L.L., Vestal, R.E., 1991. Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. *West. J. Med.* 155 (4), 410–412.
- Foley, S., Butlin, E., Shields, W., Lacey, B., 2014. Experience with OxyELITE pro and acute liver injury in active duty service members. *Dig. Dis. Sci.* 59 (12), 3117–3121.
- Fong, T.L., Klontz, K.C., Canas-Coto, A., Casper, S.J., Durazo, F.A., Davern 2nd, T.J., Hayashi, P., Lee, W.M., Seeff, L.B., 2010. Hepatotoxicity due to hydroxycut: a case series. *Am. J. Gastroenterol.* 105 (7), 1561–1566.
- Fontana, R.J., Hayashi, P.H., Gu, J., Reddy, K.R., Barnhart, H., Watkins, P.B., Serrano, J., Lee, W.M., Chalasanani, N., Stolz, A., Davern, T., Talwalkar, J.A., 2014. DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology* 147 (1), 96–108.
- Fontana, R.J., Seeff, L.B., Andrade, R.J., Björnsson, E., Day, C.P., Serrano, J., Hoofnagle, J.H., 2010. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. *Hepatology* 52 (2), 730–742.
- Forouhar, F., Nadel, M.S., Gondos, B., 1984. Hepatic pathology in vitamin A toxicity. *Ann. Clin. Lab. Sci.* 14 (4), 304–310.
- Fox, D.W., Hart, M.C., Bergeson, P.S., Jarrett, P.B., Stillman, A.E., Huxtable, R.J., 1978. Pyrrolizidine (Senecio) intoxication mimicking Reye syndrome. *J. Pediatr.* 93 (6), 980–982.
- Fu, P.P., Xia, Q., Lin, G., Chou, M.W., 2004. Pyrrolizidine alkaloids—genotoxicity,

- metabolism enzymes, metabolic activation, and mechanisms. *Drug Metab. Rev.* 36 (1), 1–55.
- Fujii, H., Takagaki, N., Yoh, T., Morita, A., Ohkawara, T., Yamaguchi, K., Minami, M., Sawa, Y., Okanou, T., Ohkawara, Y., Itoh, Y., 2008. Non-prescription supplement-induced hepatitis with hyperferritinemia and mutation (H63D) in the HFE gene. *Hepatol. Res.* 38 (3), 319–323.
- García-Cortés, M., Stephens, C., Lucena, M.I., Fernández-Castañer, A., Andrade, R.J., Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos GEHAM), 2011. Causality assessment methods in drug induced liver injury: strengths and weaknesses. *J. Hepatol.* 55 (3), 683–691.
- García-Cortés, M., Borraz, Y., Lucena, M.I., Peláez, G., Salmerón, J., Diago, M., Martínez-Sierra, M.C., Navarro, J.M., Planas, R., Soria, M.J., Bruguera, M., Andrade, R.J., 2008. Liver injury induced by “natural remedies”: an analysis of cases submitted to the Spanish Liver Toxicity Registry. *Rev. Esp. Enferm. Dig.* 100 (11), 688–695 [Article in Spanish].
- Garrido-Gallego, F., Muñoz-Gómez, R., Muñoz-Codoceo, C., Delgado-Álvarez, P., Fernández-Vázquez, I., Castellano, G., 2015. Acute liver failure in a patient consuming Herbalife products and Noni juice. *Rev. Esp. Enferm. Dig.* 107 (4), 247–248.
- Georgiou, M., Sianidou, L., Hatzis, T., Papadatos, J., 1988. Koutselinis a hepatotoxicity due to *Atractylis gummifera*-L. *J. Toxicol. Clin. Toxicol.* 26 (7), 487–493.
- Geubel, A.P., De Galocsy, C., Alves, N., Rahier, J., Dive, C., 1991. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. *Gastroenterology* 100 (6), 1701–1709.
- Gloro, R., Hourmand-Ollivier, I., Mosquet, B., Mosquet, L., Rousselot, P., Salamé, E., Piquet, M.A., Dao, T., 2005. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. *Eur. J. Gastroenterol. Hepatol.* 17 (10), 1135–1137.
- Goksu, E., Kilic, T., Yilmaz, D., 2012. Hepatitis: a herbal remedy German. *Clin. Toxicol. (Phila)* 50 (2), 158.
- Gordon, D.W., et al., 1995. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. *JAMA* 273 (6), 489–490.
- Gori, L., Galluzzi, P., Mascherini, V., Gallo, E., Lapi, F., Menniti-Ippolito, F., Raschetti, R., Mugelli, A., Vannacci, A., Firenzuoli, F., 2011. Two contemporary cases of hepatitis associated with *Teucrium chamaedrys* L. decoction use: case reports and review of literature. *Basic Clin. Pharmacol. Toxicol.* 109 (6), 521–526.
- Gow, P.J., Connelly, N.J., Hill, R.L., Crowley, P., Angus, P.W., 2003. Fatal fulminant hepatic failure induced by a natural therapy containing kava. *Med. J. Aust.* 178, 442–443.
- Guan, Y.S., 2006. A case report of hepatic veno-occlusive disease after ingesting dainties. *World J. Gastroenterol.* 12 (41), 6734–6735.
- Gunawan, B., Kaplowitz, N., 2004. Clinical perspectives on xenobiotic-induced hepatotoxicity. *Drug Metab. Rev.* 36 (2), 301–312.
- Guévar, E., Aguémon, A., 2009. Two cases of fulminant hepatitis during a curative treatment with an artesunate-amodiaquine combination. *Med. Mal. Infect.* 39 (1), 57–60 [Article in French].
- Guo, L., Shi, Q., Fang, J.L., Mei, N., Ali, A.A., Lewis, S.M., Leakey, J.E., Frankos, V.H., 2008. Review of usnic acid and Usnea barbata toxicity. *J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev.* 26 (4), 317–338.
- Guzman, G., Kallwitz, E.R., Wojewoda, C., Chennuri, R., Berkes, J., Layden, T.J., Cotler, S.J., 2009. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. *Case Rep. Med.* 2009, 918156.
- Haaz, S., Fontaine, K.R., Cutter, G., Limdi, N., Perumean-Chaney, S., Allison, D.B., 2006. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. *Obes. Rev.* 7 (1), 79–88.
- Haimowitz, S., Hsieh, J., Shcherba, M., Averbukh, Y., 2015. Liver failure after Hydroxycut™ use in a patient with undiagnosed hereditary coproporphria. *J. Gen. Intern. Med.* 30 (6), 856–859.
- Hamid, S., Rojter, S., Vierling, J., 1997. Protracted cholestatic hepatitis after the use of prostatic. *Ann. Intern. Med.* 127 (2), 169–170.
- Hamouda, C., Amamou, M., Thabet, H., Yacoub, M., Hedhili, A., Bescharnia, F., Ben Salah, N., Zhioua, M., Abdelmoumen, S., El Mekki Ben Brahim, N., 2000. Plant poisonings from herbal medication admitted to a Tunisian toxicologic intensive care unit, 1983–1998. *Vet. Hum. Toxicol.* 42 (3), 137–141.
- Hamouda, C., Hédhili, A., Ben Salah, N., Zhioua, M., Amamou, M., 2004. A review of acute poisoning from *Atractylis gummifera* L. *Vet. Hum. Toxicol.* 46 (3), 144–146.
- Hardeman, E., Van Overbeke, L., Ilegems, S., Ferrante, M., 2008. Acute hepatitis induced by greater celandine (*Chelidonium majus*). *Acta Gastroenterol. Belg.* 71 (2), 281–282.
- Harvey, J., Colin-Jones, D.G., 1981. Mistletoe hepatitis. *Br. Med. J. Clin. Res. Ed.* 282 (6259), 186–187.
- Hayman, R.M., Dalziel, S.R., 2012. Acute vitamin A toxicity: a report of three paediatric cases. *J. Paediatr. Child. Health* 48 (3), E98–E100.
- Horowitz, R.S., Feldhaus, K., Dart, R.C., Stermitz, F.R., Beck, J.J., 1996. The clinical spectrum of Jin Bu Huan toxicity. *Arch. Intern. Med.* 156, 899–903.
- Hsu, L.M., Huang, Y.S., Chang, F.Y., Lee, S.D., 2005. ‘Fat burner’ herb, usnic acid, induced acute hepatitis in a family. *J. Gastroenterol. Hepatol.* 20 (7), 1138–1139.
- Hu, Z., Yang, X., Ho, P.C., Chan, S.Y., Heng, P.W., Chan, E., Duan, W., Koh, H.L., Zhou, S., 2005. Herb-drug interactions: a literature review. *Drugs* 65 (9), 1239–1282.
- Hullar, T.E., Sapers, B.L., Ridker, P.M., Jenkins, R.L., Huth, T.S., Farraye, F.A., 1999. Herbal toxicity and fatal hepatic failure. *Am. J. Med.* 106 (2), 267–268.
- Humberston, C.L., Akhtar, J., Krenzelok, E.P., 2003. Acute hepatitis induced by kava kava. *J. Toxicol. Clin. Toxicol.* 41 (2), 109–113.
- Iacovelli, R., Palazzo, A., Procopio, G., Santoni, M., Trenta, P., De Benedetto, A., Mezi, S., Cortesi, E., 2014. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. *Br. J. Clin. Pharmacol.* 77 (6), 929–938.
- Jacobsen, C., Semb, S., Kromann-Andersen, H., 2009. Toxic hepatitis following consumption of the herbal medicinal product *Cascara Sagrada*. *Ugeskr. Laeger* 171, 3367–3369. Danish.
- Jeukendrup, A.E., Randell, R., 2011. Fat burners: nutrition supplements that increase fat metabolism. *Obes. Rev.* 12 (10), 841–851.
- Jibrin, I., Erinle, A., Saidi, A., Aliyu, Z.Y., 2006. Saw palmetto-induced pancreatitis. *South Med. J.* 99 (6), 611–612.
- Jiménez-Encarnación, E., Ríos, G., Muñoz-Mirabal, A., Vilá, L.M., 2012. Euforia-induced acute hepatitis in a patient with scleroderma. *BMJ Case Rep.* pii: bcr2012006907.
- Jimenez-Saenz, M., Martinez-Sanchez Mdel, C., 2006. Acute hepatitis associated with the use of green tea infusions. *J. Hepatol.* 44 (3), 616–617.
- Jóhannsson, M., Ormarsdóttir, S., Olafsson, S., 2010. [Hepatotoxicity associated with the use of Herbalife]. [Article Icel. Laeknabladid 96 (3), 167–172.
- Johnston, D.I., Chang, A., Viray, M., Chatham-Stephens, K., He, H., Taylor, E., Wong, L.L., Schier, J., Martin, C.Z., Fabricant, D., Salter, M., Lewis, L., Park, S.Y., 2016. Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ - Hawaii, 2013. *Drug Test. Anal.* (3–4), 319–327.
- Jones, F.J., Andrews, A.H., 2007. Acute liver injury associated with the herbal supplement hydroxycut in a soldier deployed to Iraq. *Am. J. Gastroenterol.* 102 (10), 2357–2358.
- Joshi, D., Cross, T.J., Wong, V.S., 2007. Acute drug induced hepatitis secondary to a weight loss product purchased over the internet. *Nutr. J.* 6, 13.
- Joy, D., Joy, J., Duane, P., 2008. Black cohosh: a cause of abnormal postmenopausal liver function tests. *Climacteric* 11 (1), 84–88.
- Jorge, O.A., Jorge, A.D., 2005. Hepatotoxicity associated with the ingestion of Centella asiatica. *Rev. Esp. Enferm. Dig.* 97 (2), 115–124.
- Kafrouni, M.I., Anders, R.A., Verma, S., 2007. Hepatotoxicity associated with dietary supplements containing anabolic steroids. *Clin. Gastroenterol. Hepatol.* 5 (7), 809–812.
- Kanat, O., Ozet, A., Ataergin, S., 2006. Aloe vera-induced acute toxic hepatitis in a healthy young man. *Eur. J. Intern. Med.* 17, 589.
- Kaplowitz, N., 2001. Causality assessment versus guilt-by-association in drug hepatotoxicity. *Hepatology* 33 (1), 308–310.
- Kaplowitz, N., 2004. Drug-induced liver injury. *Clin. Infect. Dis.* 1 (38), S44–S48. Suppl 2.
- Kaswala, D., Shah, S., Patel, N., Raisoni, S., Swaminathan, S., 2014. Hydroxycut-induced liver toxicity. *Ann. Med. Health Sci. Res.* 4 (1), 143–145.
- Katz, M., Saibil, F., 1990. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. *J. Clin. Gastroenterol.* 12 (2), 203–206.
- Kawaguchi, T., Harada, M., Arimatsu, H., Nagata, S., Koga, Y., Kuwahara, R., Hisamochi, A., Hino, T., Taniguchi, E., Kumemura, H., Hanada, S., Maeyama, M., Koga, H., Tomiyasu, N., Toyomasu, H., Kawaguchi, M., Kage, M., Kumashiro, R., Tanikawa, K., Sata, M., 2004. Severe hepatotoxicity associated with a N-nitrosofenfluramine-containing weight-loss supplement: report of three cases. *J. Gastroenterol. Hepatol.* 19 (3), 349–350.
- Kawata, K., Takehira, Y., Kobayashi, Y., Kitagawa, M., Yamada, M., Hanajima, K., Murohisa, G., Kawamura, M., Iwaoka, Y., Wada, T., Morita, S., Iwaizumi, M., Makino, S., 2003. Three cases of liver injury caused by Sennomotokounou, a Chinese dietary supplement for weight loss. *Intern. Med.* 42 (12), 1188–1192.
- Kauma, H., Koskela, R., Mäksälä, H., Autio-Harmainen, H., Lehtola, J., Höckerstedt, K., 2004. Toxic acute hepatitis and hepatic fibrosis after consumption of chaparral tablets. *Scand. J. Gastroenterol.* 39 (11), 1168–1171.
- Kim, S.Y., Yim, H.J., Ahn, J.H., Kim, J.H., Kim, J.N., Yoon, I., Kim, D.I., Lee, H.S., Lee, S.W., Choi, J.H., 2009. Two cases of toxic hepatitis caused by arrowroot juice. *Korean J. Hepatol.* 15 (4), 504–509 [Article in Korean].
- Kockler, D.R., McCarthy, M.W., Lawson, C.L., 2001. Seizure activity and unresponsiveness after hydroxycut ingestion. *Pharmacotherapy* 21 (5), 647–651.
- Kowalski, T.E., Falestiny, M., Furth, E., Malet, P.F., 1994. Vitamin A hepatotoxicity: a cautionary note regarding 25,000 IU supplements. *Am. J. Med.* 97 (6), 523–528.
- Kraft, M., Spahn, T.W., Menzel, J., Senninger, N., Dieltz, K.H., Herbst, H., Domschke, W., Lerch, M.M., 2001. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. *Dtsch. Med. Wochenschr.* 126 (36), 970–972 [Article in German].
- Krishna, K.P., 2011. The efficacy of Ayurvedic treatment for rheumatoid arthritis: cross-sectional experiential profile of a longitudinal study. *Int. J. Ayurveda Res.* 2 (1), 8–13.
- Krishnan, P.V., Feng, Z.Z., Gordon, S.C., 2009. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. *J. Clin. Gastroenterol.* 43 (7), 672–675.
- Laczek, J., Duncan, M., 2008. Three cases of acute hepatitis in patients taking hydroxycut bodybuilding supplement. *Am. J. Gastroenterol.* 103, S143–S144.
- Lai, R.T., Wang, H., Gui, H.L., Ye, M.Z., Dai, W.J., Xiang, X.G., Zhao, G.D., Wang, W.J., Xie, Q., 2012. Clinical and pathological features in 138 cases of drug-induced liver injury. *Zhonghua Gan Zang Bing Za Zhi* 20 (3), 185–189 [Article in Chinese].
- Laliberte, L., Villeneuve, J.P., 1996. Hepatitis after the use of germander, a herbal remedy. *CMAJ* 154 (11), 1689–1692.
- Lapi, F., Gallo, E., Giocaliere, E., Vietri, M., Baronti, R., Pieraccini, G., Taft, A., Menniti-Ippolito, F., Mugelli, A., Firenzuoli, F., Vannacci, A., 2010. Acute liver damage due to *Serenia repens*: a case report. *Br. J. Clin. Pharmacol.* 69 (5), 558–560.

- Larrey, D., 1997. Hepatotoxicity of herbal remedies. *J. Hepatol.* 26 (Suppl. 1), 47–51.
- Larrey, D., Pageaux, G.P., 2005. Drug-induced acute liver failure. *Eur. J. Gastroenterol. Hepatol.* 17 (2), 141–143.
- Larrey, D., Vial, T., Pauwels, A., Castot, A., Biour, M., David, M., Michel, H., 1992. Hepatitis after germander (*Teucrium chamaedrys*) administration: another instance of herbal medicine hepatotoxicity. *Ann. Intern. Med.* 117 (2), 129–132.
- Lee, J., Lee, M.S., Nam, K.W., 2014. Acute toxic hepatitis caused by an aloe vera preparation in a young patient: a case report with a literature review. *Korean J. Gastroenterol.* 64 (1), 54–58.
- Lee, J.S., Cheong, H.S., Kim, L.H., Kim, J.O., Seo, D.W., Kim, Y.H., Chung, M.W., Han, S.Y., Shin, H.D., 2013. Screening of genetic polymorphisms of CYP3A4 and CYP3A5 genes. *Korean J. Physiol. Pharmacol.* 17 (6), 479–484.
- Lee, W.M., 2012. Acute liver failure. *Semin. Respir. Crit. Care Med.* 33 (1), 36–45.
- Legoux, J.L., Maitre, F., Labarrière, D., Gargot, D., Festin, D., Causse, X., 1992. Cytolytic hepatitis and wild Germander: a new case with reintroduction. *Gastroenterol. Clin. Biol.* 16 (10), 813–815 [Article in French].
- Leise, M.D., Poterucha, J.J., Talwalkar, J.A., 2014. Drug-induced liver injury. *Mayo Clin. Proc.* 89 (1), 95–106.
- Lemaigre, G., Tebbi, Z., Galinsky, R., Michowitz, S., Abelanet, R., 1975 Nov 22. Fulminating hepatitis caused by glue thistle (*Atractylis glummifera-L.*), poisoning. Anatomic-pathological study of 4 cases. *Nouv. Presse Med.* 4 (40), 2565–2568 [Article in French].
- Levitsky, J., Alli, T.A., Wisecarver, J., Sorrell, M.F., 2005. Fulminant liver failure associated with the use of black cohosh. *Dig. Dis. Sci.* 50 (3), 538–539.
- Licatta, A., Macaluso, F.S., Craxi, A., 2013. Herbal hepatotoxicity: a hidden epidemic. *Intern. Emerg. Med.* 8 (1), 13–22.
- Licatta, A., Maida, M., Cabibi, D., Butera, G., Macaluso, F.S., Alessi, N., Caruso, C., Craxi, A., Almasio, P.L., 2014. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. *Dig. Liver Dis.* 46 (12), 1116–1120.
- Linnebur, S.A., Rapachietta, O.C., Vejar, M., 2010. Hepatotoxicity associated with Chinese skullcap contained in Move Free Advanced dietary supplement: two case reports and review of the literature. *Pharmacotherapy* 30 (7), 750, 258e–262e.
- Lobb, A., 2009. Hepatotoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. *World J. Gastroenterol.* 15 (14), 1786–1787.
- Lonie, T.C., 1950. Excess vitamin A as a cause of food poisoning. *N. Z. Med. J.* 49 (274), 680–685.
- Long, J., 11/7/2013. USPlabs to Eliminate Aegeline from Supplements amid Hepatitis Probe. <http://www.naturalproductsinsider.com/news/2013/11/usplabs-to-eliminate-aegeline-from-supplements-am.aspx> (accessed 15.12.15.).
- Lontos, S., Jones, R.M., Angus, P.W., Gow, P.J., 2003. Acute liver failure associated with the use of herbal preparations containing black cohosh. *Med. J. Aust.* 179 (7), 390–391.
- Lucena, M.I., Molokhia, M., Shen, Y., Urban, T.J., Aithal, G.P., Andrade, R.J., Day, C.P., Ruiz-Cabello, F., Donaldson, P.T., Stephens, C., Pirmohamed, M., Romero-Gomez, M., Navarro, J.M., Fontana, R.J., Miller, M., Groome, M., Bondon-Guitton, E., Conforti, A., Stricker, B.H., Carvajal, A., Ibanez, L., Yue, Q.Y., Eichelbaum, M., Floratos, A., Pe'er, I., Daly, M.J., Goldstein, D.B., Dillon, J.F., Nelson, M.R., Watkins, P.B., Daly, A.K., 2011. Spanish DILI Registry; Eudragene; Diliin; Diliin; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology* 141 (1), 338–347.
- Luu, L. Liver transplants. Practice essentials. <http://emedicine.medscape.com/article/776313-overview>. (accessed 23.11.15.).
- Lyford, C.L., Vergara, G.G., Moeller, D.D., 1976. Hepatic veno-occlusive disease originating in Ecuador. *Gastroenterology* 70 (1), 105–108.
- Lynch, C.R., Folkers, M.E., Hutson, W.R., 2006. Fulminant hepatic failure associated with the use of black cohosh: a case report. *Liver Transpl.* 126, 989–992.
- MacGregor, F.B., Abernethy, V.E., Dahabra, S., Cobden, I., Hayes, P.C., 1989. Hepatotoxicity of herbal remedies. *BMJ* 299 (6708), 1156–1157.
- Mahady, G.B., Low Dog, T., Barrett, M.L., Chavez, M.L., Gardiner, P., Ko, R., Marles, R.J., Pellicore, L.S., Giancaspro, G.I., Sarma, D.N., 2008. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. *Menopause* 15 (4 Pt 1), 628–638.
- Mahady, G., Low Dog, T., Sarma, D.N., Giancaspro, G.I., 2009 Oct 20. Suspected black cohosh hepatotoxicity—causality assessment versus safety signal. *Maturitas* 64 (2), 139–140 author reply 141–2.
- Manso, G., López-Rivas, L., Salgueiro, M.E., Duque, J.M., Jimeno, F.J., Andrade, R.J., Lucena, M.I., 2011. Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. *Pharmacoepidemiol. Drug Saf.* 20 (10), 1080–1087.
- Marcus, D.M., Grollman, A.P., 2002. Botanical medicines—the need for new regulations. *N. Engl. J. Med.* 347 (25), 2073–2076.
- Maria, V.A., Victorino, R.M., 1997. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. *Hepatology* 26, 664–669.
- Mattéi, A., Rucay, P., Samuel, D., Fera, C., Reynes, M., Bismuth, H., 1995. Liver transplantation for severe acute liver failure after herbal medicine (*Teucrium polium*) administration. *J. Hepatol.* 22 (5), 597.
- Mattéi, A., Bizollon, T., Charles, J.D., Debat, P., Fontanges, T., Chevallier, M., Trepo, C., 1992. Liver damage induced by the ingestion of a product of phytotherapy containing wild germander. Four cases. *Gastroenterol. Clin. Biol.* 16 (10), 798–800 [Article in French].
- Mazokopakis, E., Lazaridou, S., Tzardi, M., Mixaki, J., Diamantis, I., Ganotakis, E., 2004. Acute cholestatic hepatitis caused by *Teucrium polium* L. *Phytomedicine* 11 (1), 83–84.
- Mazzanti, G., Di Sotto, A., Vitalone, A., 2015. Hepatotoxicity of green tea: an update. *Arch. Toxicol.* 89 (8), 1175–1191.
- McDonnell, W.M., Bhattacharya, R., Hallderson, J.B., 2009. Fulminant hepatic failure after use of the herbal weight-loss supplement exilis. *Ann. Intern. Med.* 151 (9), 673–674.
- McGuffin, M., 2013. Illegally marketed drug ingredients are not dietary supplements. *JAMA Intern. Med.* 173 (22), 2090–2091.
- Mengual-Moreno, E., Lizarzábal-García, M., Ruiz-Soler, M., Silva-Suarez, N., Andrade-Bellido, R., Lucena-González, M., Bessone, F., Hernández, N., Sánchez, A., Medina-Cáliz, I., 2015. Case reports of drug-induced liver injury in a reference hospital of Zulia state, Venezuela. *Invest. Clin.* 56 (1), 3–12 [Article in Spanish].
- Miksad, R., de Lédinghen, V., McDougall, C., Fiel, I., Rosenberg, H., 2002. Hepatic hydrothorax associated with vitamin A toxicity. *J. Clin. Gastroenterol.* 34 (3), 275–279.
- Millonig, G., Stadlmann, S., Vogel, W., 2005. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (*Morinda citrifolia*). *Eur. J. Gastroenterol. Hepatol.* 17 (4), 445–447.
- Mimidis, K.P., Papadopoulos, V.P., Baltatzidis, G., Giatromanolaki, A., Sivridis, E., Kartalis, G., 2009. Severe acute cholestasis caused by *Teucrium polium*. *J. Gastrointest. Liver Dis.* 18 (3), 387–388.
- Minuk, G.Y., Kelly, J.K., Hwang, W.S., 1988. Vitamin A hepatotoxicity in multiple family members. *Hepatology* 8 (2), 272–275.
- Molinari, M., Watt, K.D., Kruszyna, T., Nelson, R., Walsh, M., Huang, W.Y., Nashan, B., Peltekian, K., 2006. Acute liver failure induced by green tea extracts: case report and review of the literature. *Liver Transpl.* 12 (12), 1892–1895.
- Moro, P.A., Cassetti, F., Giugliano, G., Falce, M.T., Mazzanti, G., Menniti-Ippolito, F., Raschetti, R., Santuccio, C., 2009. Hepatitis from Greater celandine (*Chelidonium majus* L.): review of literature and report of a new case. *J. Ethnopharmacol.* 124 (2), 328–332.
- Mostefa-Kara, N., Pauwels, A., Pines, E., Biour, M., et al., 1992. Fatal hepatitis after herbal tea. *Lancet* 340 (8820), 674.
- Mounajjed, T., Graham, R.P., Sanderson, S.O., Smyrk, T.C., 2014. Clinical associations of hepatic stellate cell (HSC) hyperplasia. *Virchows Arch.* 465 (1), 57–65.
- Mrzljak, A., Kosuta, I., Skrtic, A., Kanizaj, T.F., Vrhovac, R., 2013. Drug-induced liver injury associated with noni (*Morinda citrifolia*) juice and phenobarbital. *Case Rep. Gastroenterol.* 7, 19–24.
- Munoz, S.J., Fariello, R., Maddrey, W.C., 1988. Submassive hepatic necrosis associated with the use of progabide: a GABA receptor agonist. *Dig. Dis. Sci.* 33 (3), 375–380.
- Muqet Adnan, M., Khan, M., Hashmi, S., Hamza, M., AbdulMujeeb, S., Amer, S., 2014. Black cohosh and liver toxicity: is there a relationship? *Case Rep. Gastrointest. Med.* 2014, 860614.
- Nadir, A., Agrawal, S., King, P.D., Marshall, J.B., 1996. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. *Am. J. Gastroenterol.* 91 (7), 1436–1438.
- Nadir, A., Reddy, D., Van Thiel, D.H., 2000. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity. *Am. J. Gastroenterol.* 95 (12), 3634–3637.
- Nakasono, E.S., Tokeshi, J., 2015. A serendipitous find: a case of cholangiocarcinoma identified incidentally after acute liver injury due to cascara sagrada ingestion. *Hawaii J. Med. Public Health* 74 (6), 200–202.
- Nam, S.W., Baek, J.T., Lee, D.S., Kang, S.B., Ahn, B.M., Chung, K.W., 2005. A case of acute cholestatic hepatitis associated with the seeds of *Psoralea corylifolia* (Boh-Gol-Zhee). *Clin. Toxicol. (Phila)* 43 (6), 589–591.
- Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., Janacek, E., Domecq, C., Greenblatt, D.J., 1981a. A method for estimating the probability of adverse drug reactions. *Clin. Pharmacol. Ther.* 30 (2), 239–245.
- Navarro, V.J., Bonkovsky, H.L., Hwang, S.L., Vega, M., Barnhart, H., Serrano, J., 2013. Catechins in dietary supplements and hepatotoxicity. *Dig. Dis. Sci.* 58 (9), 2682–2690.
- Navarro, V.J., Lucena, M.I., 2014. Hepatotoxicity induced by herbal and dietary supplements. *Semin. Liver Dis.* 34 (2), 172–193.
- Navarro, V.J., Barnhart, H., Bonkovsky, H.L., Davern, T., Fontana, R.J., Grant, L., Reddy, K.R., Seeff, L.B., Serrano, J., Sherker, A.H., Stolz, A., Talwalkar, J., Vega, M., Vuppalanchi, R., 2014. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. *Hepatology* 60 (4), 1399–1408.
- Navarro, V.J., Seeff, L.B., 2013. Liver injury induced by herbal complementary and alternative medicine. *Clin. Liver Dis.* 17 (4), 715–735.
- Neerghen-Bhujun, V.S., 2013. Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries. *Biomed. Res. Int.* 2013, 804086.
- Neff, G.W., Reddy, K.R., Durazo, F.A., Meyer, D., Marrero, R., Kaplowitz, N., 2004. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. *J. Hepatol.* 41 (6), 1062–1064.
- Nencini, C., Galluzzi, P., Pippi, F., Menchiarì, A., Micheli, L., 2014. Hepatotoxicity of *Teucrium chamaedrys* L. decoction: role of difference in the harvesting area and preparation method. *Indian J. Pharmacol.* 46 (2), 181–184.
- Nisbet, B.C., O'Connor, R.E., 2007. Black cohosh-induced hepatitis. *Del Med. J.* 79 (11), 441–444.
- Nortadas, R., Barata, J., 2012. Fulminant hepatitis during self-medication with conjugated linoleic acid. *Ann. Hepatol.* 11 (2), 265–267.
- Nowack, R., Nowak, B., 2005. Herbal teas interfere with cyclosporin levels in renal transplant patients. *Nephrol. Dial. Transpl.* 20 (11), 2554–2556.

- O'Donnell, J., 2004. Polar hysteria: an expression of hypervitaminosis A. *Am. J. Ther.* 11 (6), 507–516.
- O'hara, M., Kiefer, D., Farrell, K., Kemper, K., et al., 1998. A review of 12 commonly used medicinal herbs. *Arch. Fam. Med.* 7 (6), 523–536.
- Ortiz Cansado, A., Crespo Valadés, E., Morales Blanco, P., Sáenz de Santamaría, J., González Campillejo, J.M., Ruiz Téllez, T., 1995. Veno-occlusive liver disease due to intake of *Senecio vulgaris* tea. *Gastroenterol. Hepatol.* 18 (8), 413–416 [Article in Spanish].
- Ossendza, R.A., Grandval, P., Chinoune, F., Rocher, F., Chapel, F., Bernardini, D., 2007. Acute cholestatic hepatitis due to glucosamine forte. *Gastroenterol. Clin. Biol.* 31 (4), 449–450 [Article in French].
- Patel, D.N., Low, W.L., Tan, L.L., Tan, M.M., Zhang, Q., Low, M.Y., Chan, C.L., Koh, H.L., 2012. Adverse events associated with the use of complementary medicine and health supplements: an analysis of reports in the Singapore Pharmacovigilance database from 1998 to 2009. *Clin. Toxicol. (Phila)* 50 (6), 481–489.
- Patel, S.S., Beer, S., Kearney, D.L., Phillips, G., Carter, B.A., 2013. Green tea extract: a potential cause of acute liver failure. *World Gastroenterol.* 19 (31), 5174–5177.
- Pauwels, A., Thierman-Duffaud, D., Azanowsky, J.M., Loiseau, D., Biour, M., Levy, V.G., 1992. Acute hepatitis caused by wild germander. Hepatotoxicity of herbal remedies. Two cases. *Gastroenterol. Clin. Biol.* 16 (1), 92–95 [Article in French].
- PDR Staff, 2016. Physicians' Desk Reference, 70th Edition. PDR Network.
- Pedrés, C., Cereza, G., García, N., Laporte, J.R., 2003. Liver toxicity of *Camellia sinensis* dried etanolic extract. *Med. Clin. Barc.* 121 (15), 598–599 [Article in Spanish].
- Pérez Alvarez, J., Sáez-Royuela, F., Gento Peña, E., López Morante, A., Velasco Osés, A., Martín Lorente, J., 2001. Acute hepatitis due to ingestion of *Teucrium chamaedrys* infusions. *Gastroenterol. Hepatol.* 24 (5), 240–243 [Article in Spanish].
- Piccioletto, A., Campo, N., Brizzolaro, R., Giusto, R., et al., 1998. Chronic hepatitis induced by jin bu huan. *J. Hepatol.* 28 (1), 156–157.
- Pierard, S., Coche, J.C., Lanthier, P., Dekoninck, X., Lanthier, N., Rahier, J., Geubel, A.P., 2009. Severe hepatitis associated with the use of black cohosh: a report of two cases and an advice for caution. *Eur. J. Gastroenterol. Hepatol.* 21 (8), 941–945.
- Pillukat, M.H., Bester, C., Hensel, A., Lechtenberg, M., Peterleit, F., Beckebaum, S., Müller, K.M., Schmidt, H.H., 2014. Concentrated green tea extract induces severe acute hepatitis in a 63-year-old woman—a case report with pharmaceutical analysis. *J. Ethnopharmacol.* 155 (1), 165–170.
- Pittler, M.H., Ernst, E., 2003. Systematic review: hepatotoxic events associated with herbal medicinal products. *Aliment. Pharmacol. Ther.* 18 (5), 451–471.
- Polymeros, D., Kamberoglou, D., Tzias, V., 2002. Acute cholestatic hepatitis caused by *Teucrium polium* (golden germander) with transient appearance of anti-mitochondrial antibody. *J. Clin. Gastroenterol.* 34 (1), 100–101.
- Poon, W.T., Chau, T.L., Lai, C.K., Tse, K.Y., Chan, Y.C., Leung, K.S., Chan, Y.W., 2008. Hepatitis induced by *Teucrium viscidum*. *Clin. Toxicol. (Phila)* 46 (9), 819–822.
- Posadzki, P., Watson, L., Ernst, E., 2013. Herb-drug interactions: an overview of systematic reviews. *Br. J. Clin. Pharmacol.* 75 (3), 603–618.
- Rabe, C., Musch, A., Schirmacher, P., Kruiis, W., Hoffmann, R., 2005. Acute hepatitis induced by an aloe vera preparation: a case report. *World J. Gastroenterol.* 11, 303–304.
- Rader, J.I., Calvert, R.J., Hathcock, J.N., 1992. Hepatic toxicity of unmodified and time-release preparations of niacin. *Am. J. Med.* 92 (1), 77–81.
- Rahimi, R., Abdollahi, M., 2012. An update on the ability of St. John's wort to affect the metabolism of other drugs. *Expert Opin. Drug Metab. Toxicol.* 8 (6), 691–708.
- Rahnema, C.D., Crosnoe, L.E., Kim, E.D., 2015. Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem. *Andrology* 3 (2), 150–155.
- Ramanathan, V.S., Hensley, G., French, S., Eysselein, V., Chung, D., Reicher, S., Pham, B., 2010. Hypervitaminosis A inducing intra-hepatic cholestasis—a rare case report. *Exp. Mol. Pathol.* 88 (2), 324–325.
- Ramanathan, V.S., Mitropoulos, E., Shlopov, B., Eysselein, V., Chung, D., Reicher, S., Pham, B.V., 2011. An Enzyte'ing' case of acute hepatitis. *J. Clin. Gastroenterol.* 45 (9), 834–835.
- Ramos, R., Mascarenhas, J., Duarte, P., Vicente, C., Casteleiro, C., 2009. Conjugated linoleic acid-induced toxic hepatitis: first case report. *Dig. Dis. Sci.* 54 (5), 1141–1143.
- Raschi, E., De Ponti, F., 2015. Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk. *World J. Hepatol.* 7 (13), 1761–1771.
- Rashid, N.N., Grant, J., 2010. Hydroxycut hepatotoxicity. *Med. J. Aust.* 192 (3), 173–174.
- Ridker, P.M., Ohkuma, S., McDermott, W.V., Trey, C., Huxtable, R.J., 1985. Hepatic venoocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. *Gastroenterology* 88 (4), 1050–1054.
- Rifai, K., Flemming, P., Manns, M.P., Trautwein, C., 2006. Severe drug hepatitis caused by *Chelidonium*. *Internist (Berl)* 47 (7), 749–751 [Article in German].
- Roeder, E., 2000. Medicinal plants in China containing pyrrolizidine alkaloids. *Pharmazie* 55 (10), 711–726.
- Rohilla, R., Garg, T., Goyal, A.K., Rath, G., 2016. Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance. *Drug Deliv.* 23 (5), 1645–1661.
- Roselle, H., Ekatan, A., Tzeng, J., Sapienza, M., Kocher, J., 2008. Symptomatic hepatitis associated with the use of herbal red yeast rice. *Ann. Intern Med.* 149 (7), 516–517.
- Roytman, M.M., Pörzgen, P., Lee, C.L., Huddleston, L., Kuo, T.T., Bryant-Greenwood, P., Wong, L.L., Tsai, N., 2014. Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. *Am. J. Gastroenterol.* 109 (8), 1296–1298.
- Russmann, S., Lauterburg, B.H., Helbling, A., 2001. Kava hepatotoxicity. *Ann. Intern Med.* 135 (1), 68–69.
- Russo, M.W., Galanko, J.A., Shrestha, R., Fried, M.W., Watkins, P., 2004. Liver transplantation for acute liver failure from drug induced liver injury in the United States. *Liver Transpl.* 10 (8), 1018–1023.
- Safi, K.H., Filbrun, A.G., Nasr, S.Z., 2014. Hypervitaminosis A causing hypercalcemia in cystic fibrosis. Case report and focused review. *Ann. Am. Thorac. Soc.* 11 (8), 1244–1247.
- Sanchez, W., Maple, J.T., Burgart, L.J., Kamath, P.S., 2006. Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. *Mayo Clin. Proc.* 81 (4), 541–544.
- Sansone, R.A., Sansone, L.A., 2012. Carrot man: a case of excessive beta-carotene ingestion. *Int. J. Eat. Disord.* 45 (6), 816–818.
- Sarma, D.N., Barrett, M.L., Chavez, M.L., Gardiner, P., Ko, R., Mahady, G.B., Marles, R.J., Pellicore, L.S., Giancaspro, G.I., Low Dog, T., 2008. Safety of green tea extracts: a systematic review by the US Pharmacopeia. *Drug Saf.* 31 (6), 469–484.
- Savvidou, S., Goulis, J., Giavazis, I., Patsiaoura, K., Hytioglou, P., Arvanitakis, C., 2007. Herb-induced hepatitis by *Teucrium polium* L.: report of two cases and review of the literature. *Eur. J. Gastroenterol. Hepatol.* 19 (6), 507–511.
- Schiano, T.D., 2003. Hepatotoxicity and complementary and alternative medicines. *Clin. Liver Dis.* 7 (2), 453–473.
- Schoepfer, A.M., Engel, A., Fattinger, K., Marbet, U.A., Criblez, D., Reichen, J., Zimmermann, A., Oneta, C.M., 2007. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. *J. Hepatol.* 47 (4), 521–526.
- Scott, B.A., Troppmann, C., Rossaro, L., 2003. Hepatotoxicity associated with a dietary supplement. *Ann. Intern Med.* 138 (8), W-49.
- Seeff, L.B., Bonkovsky, H.L., Navarro, V.J., Wang, G., 2015. Herbal products and the liver: a review of adverse effects and mechanisms. *Gastroenterology* 148 (3), 517–532.
- Semwal, R.B., Semwal, D.K., Vermaak, I., Viljoen, A., 2015. A comprehensive scientific overview of *Garcinia cambogia*. *Fitoterapia* 102, 134–148.
- Seybold, U., Landauer, N., Hillebrand, S., Goebel, F.D., 2004. Senna-induced hepatitis in a poor metabolizer. *Ann. Intern Med.* 141 (8), 650–651.
- Sezer, R.G., Bozaykut, A., 2012. Pediatric hepatotoxicity associated with polygermander (*teucrium polium*). *Clin. Toxicol. (Phila)* 50 (2), 153.
- Shad, J.A., Chinn, C.G., Brann, O.S., 1999. Acute hepatitis after ingestion of herbs. *South Med. J.* 92 (11), 1095–1097.
- Shah, N.L., Zacharias, I., Khettry, U., Afdhal, N., Gordon, F.D., 2008. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. *Clin. Gastroenterol. Hepatol.* 6 (2), 255–258.
- Sharma, T., Wong, L., Tsai, N., Wong, R.D., 2010. Hydroxycut[®] (herbal weight loss supplement) induced hepatotoxicity: a case report and review of literature. *Hawaii Med. J.* 69 (8), 188–190.
- Sheikh, N.M., Philen, R.M., Love, L.A., 1997. Chaparral-associated hepatotoxicity. *Arch. Intern Med.* 157 (8), 913–919.
- Sheth, A., Khurana, R., Khurana, V., 2008. Potential liver damage associated with over-the-counter vitamin supplements. *J. Am. Diet. Assoc.* 108 (9), 1536–1537.
- Shim, M., Saab, S., 2009. Severe hepatotoxicity due to Hydroxycut: a case report. *Dig. Dis. Sci.* 54 (2), 406–408.
- Shiple, A., Berkowitz, B., Rivero, C., 10/18/2005. Designer Steroids: Hide and Seek. *The Washington Post*. <http://www.washingtonpost.com/wp-dyn/content/graphic/2005/10/18/GR2005101800648.html> (accessed 30.11.15).
- Skoulidis, F., Alexander, G.J., Davies, S.E., 2005. Ma huang associated acute liver failure requiring liver transplantation. *Eur. J. Gastroenterol. Hepatol.* 17 (5), 581–584.
- Smith, A., Dillon, J., 2009. Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies. *BMJ Case Rep.* 2009 pii: bcr.02.2009.1603.
- Smith, B.C., Desmond, P.V., 1993. Acute hepatitis induced by ingestion of the herbal medication chaparral. *Aust. N. Z. J. Med.* 23 (5), 526.
- Soni, M.G., Burdock, G.A., Preuss, H.G., Stohs, S.J., Ohia, S.E., Bagchi, D., 2004. Safety assessment of (-)-hydroxycitric acid and Super CitriMax, a novel calcium/potassium salt. *Food Chem. Toxicol.* 42 (9), 1513–1529.
- Sonmez, A., Yilmaz, M.I., Mas, R., Ozcan, A., Celasun, B., Dogru, T., Taslipinar, A., Kocar, I.H., 2005. Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation. *Acta Gastroenterol. Belg.* 68 (3), 385–387.
- Stadlbauer, V., Weiss, S., Payer, F., Stauber, R.E., 2008. Herbal does not at all mean innocuous: the sixth case of hepatotoxicity associated with morinda citrifolia (noni). *Am. J. Gastroenterol.* 103 (9), 2406–2407.
- Stadlbauer, V., Fickert, P., Lackner, C., Schmerlaib, J., Krisper, P., Trauner, M., Stauber, R.E., 2005. Hepatotoxicity of NONI juice: report of two cases. *World J. Gastroenterol.* 11 (30), 4758–4760.
- Starakis, I., Siagris, D., Leonidou, L., Mazokopakis, E., Tsamandas, A., Karatza, C., 2006. Hepatitis caused by the herbal remedy *Teucrium polium* L. *Eur. J. Gastroenterol. Hepatol.* 18 (6), 681–683.
- Stedman, C., 2002. Herbal toxicity. *Semin. Liver Dis.* 22 (2), 195–206.
- Steenkamp, V., Stewart, M.J., Zuckerman, M., 1999. Detection of poisoning by *Impatiens (Callilepis laureola)* in a mother and child. *Hum. Exp. Toxicol.* 18 (10), 594–597.
- Stephens, C., López-Nevot, M.Á., Ruiz-Cabello, F., Ulzurrun, E., Soriano, G., Romero-Gómez, M., Moreno-Casares, A., Lucena, M.I., Andrade, R.J., 2013 Jul 9. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity.

- PLoS One 8 (7), e68111.
- Stevens, T., Qadri, A., Zein, N.N., 2005. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. *Ann. Intern. Med.* 142 (6), 477–478.
- Stickel, F., Baumüller, H.M., Seitz, K., Vasilakis, D., Seitz, G., Seitz, H.K., Schuppan, D., 2003a. Hepatitis induced by Kava (*Piper methysticum rhizoma*). *J. Hepatol.* 39 (1), 62–67.
- Stickel, F., Droz, S., Patsenker, E., Bögli-Stubler, K., Aebi, B., Leib, S.L., 2009. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with *Bacillus subtilis*. *J. Hepatol.* 50 (1), 111–117.
- Stickel, F., Kessebohm, K., Weimann, R., Seitz, H.K., 2011. Review of liver injury associated with dietary supplements. *Liver Int.* 31 (5), 595–605.
- Stickel, F., Patsenker, E., Schuppan, D., 2005. Herbal hepatotoxicity. *J. Hepatol.* 43 (5), 901–910.
- Stickel, F., Pöschl, G., Seitz, H.K., Waldherr, R., Hahn, E.G., Schuppan, D., 2003b. Acute hepatitis induced by greater celandine (*chelidonium majus*). *Scand. J. Gastroenterol.* 38 (5), 565–568.
- Stickel, F., Shouval, D., 2015. Hepatotoxicity of herbal and dietary supplements: an update. *Arch. Toxicol.* 89 (6), 851–865.
- Stillman, A.E., Huxtable, R.J., Fox, D., Hart, M., Bergeson, P., 1977. Pyrrolizidine (*Senecio*) poisoning in Arizona: severe liver damage due to herbal teas. *Ariz. Med.* 34 (8), 545–546.
- Stohs, S.J., Ray, S.D., 2013. A review and evaluation of the efficacy and safety of *Cissus quadrangularis* extracts. *Phytother. Res.* 27 (8), 1107–1114.
- Stohs, S.J., Preuss, H.G., Ohia, S.E., Kaats, G.R., Keen, C.L., Williams, L.D., Burdock, G.A., 2009. No evidence demonstrating hepatotoxicity associated with hydroxycitric acid. *World J. Gastroenterol.* 15 (3), 4087–4089.
- Strahl, S., Ehret, V., Dahm, H.H., Maier, K.P., 1998. Necrotizing hepatitis after taking herbal remedies. *Dtsch. Med. Wochenschr.* 123 (47), 1410–1414 [Article in German].
- Strasser, M., Stadlmayr, A., Haufe, H., Stickel, F., Ferenci, P., Patsch, W., Feldman, A., Weghuber, D., Datz, C., Aigner, E., 2015 Aug 10. Natural course of subjects with elevated liver tests and normal liver histology. *Liver Int.* ([Epub ahead of print]).
- Suk, K.T., Kim, D.J., Kim, C.H., Park, S.H., et al., 2012. A prospective nationwide study of drug-induced liver injury in Korea. *Am. J. Gastroenterol.* 107, 1380–1387.
- Sullivan Jr., J.B., Rumack, B.H., Thomas Jr., H., Peterson, R.G., Bryson, P., 1979. Pennyroyal oil poisoning and hepatotoxicity. *JAMA* 242, 2873–2874.
- Takegoshi, K., Tohyama, T., Okuda, K., Suzuki, K., Ohta, G., 1986. A case of Venoplant-induced hepatic injury. *Gastroenterol. Jpn.* 21 (1), 62–65.
- Takikawa, H., Takamori, Y., Kumagi, T., Onji, M., Watanabe, M., Shibuya, A., Hisamochi, A., Kumashiro, R., Ito, T., Mitsumoto, Y., Nakamura, A., Sakaguchi, T., 2003. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. *Hepatol. Res.* 27 (3), 192–195.
- Tandon, B.N., Tandon, H.D., Tandon, R.K., Narndranathan, M., Joshi, Y.K., 1976. An epidemic of veno-occlusive disease of liver in central India. *Lancet* 2 (7980), 271–272.
- Teschke, R., 2010a. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. *A critical review. Menopause* 17 (2), 426–440.
- Teschke, R., 2010b. Kava hepatotoxicity—a clinical review. *Ann. Hepatol.* 9 (3), 251–265.
- Teschke, R., 2014. Traditional chinese medicine induced liver injury. *J. Clin. Transl. Hepatol.* 2 (2), 80–94.
- Teschke, R., Bahre, R., 2009. Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment. *Ann. Hepatol.* 8 (3), 258–266.
- Teschke, R., Frenzel, C., Schulze, J., Eickhoff, A., 2013a. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. *World J. Gastroenterol.* 19 (19), 2864–2882.
- Teschke, R., Frenzel, C., Schulze, J., Schwarzenboeck, A., Eickhoff, A., 2013b. Herbalife hepatotoxicity: evaluation of cases with positive reexposure tests. *World J. Hepatol.* 5 (7), 353–363.
- Teschke, R., Larrey, D., Melchart, D., Dana, G., 2016. Traditional Chinese Medicine (TCM) and herbal Hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. *Medicines* 3 (18). <http://dx.doi.org/10.3390/medicines3030018>.
- Teschke, R., Schulze, J., 2012a. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. *Drug Saf.* 35 (12), 1091–1097.
- Teschke, R., Schulze, J., Schwarzenboeck, A., Eickhoff, A., Frenzel, C., 2013c. Herbal hepatotoxicity: suspected cases assessed for alternative causes. *Eur. J. Gastroenterol. Hepatol.* 25 (9), 1093–1098.
- Teschke, R., Schwarzenboeck, A., Hennermann, K.H., 2008. Causality assessment in hepatotoxicity by drugs and dietary supplements. *Br. J. Clin. Pharmacol.* 66 (6), 758–766.
- Teschke, R., Wolff, A., Frenzel, C., Schulze, J., Eickhoff, A., 2012. Herbal hepatotoxicity: a tabular compilation of reported cases. *Liver Int.* 32 (10), 1543–1556.
- Theiler, R., Wirth, H.P., Flury, R., Hanck, A., Michel, B.A., 1993. Chronic vitamin A poisoning with musculoskeletal symptoms and morphological changes of the liver: a case report. *Schweiz Med. Wochenschr.* 123 (51–52), 2405–2412 [Article in German].
- Thomasson, H.R., Crabb, D.W., Edenberg, H.J., Li, T.K., 1993. Alcohol and aldehyde dehydrogenase polymorphisms and alcoholism. *Behav. Genet.* 23 (2), 131–136.
- Urban, T.J., Daly, A.K., Aithal, G.P., 2014. Genetic basis of drug-induced liver injury: present and future. *Semin. Liver Dis.* 34 (2), 123–133.
- van de Meerendonk, H.W., van Hunsel, F.P., van der Wiel, H.E., 2009. Autoimmune hepatitis induced by *Actaea racemosa*. Side effects of an herb extract. *Ned. Tijdschr. Geneesk.* 153 (6), 246–249 [Article in Dutch].
- Vanderperren, B., Rizzo, M., Angenot, L., Haufroid, V., Jadoul, M., Hantson, P., 2005. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. *Ann. Pharmacother.* 39 (7–8), 1353–1357.
- Vannacci, A., Lapi, F., Gallo, E., Vietri, M., Toti, M., Menniti-Ippolito, F., Raschetti, R., Firenzuoli, F., Mugelli, A., 2009. A case of hepatitis associated with long-term use of *Cimicifuga racemosa*. *Altern. Ther. Health Med.* 15 (3), 62–63.
- Vassiliadis, T., Anagnostis, P., Patsiaoura, K., Giouleme, O., Katsinelos, P., Mpoumpouris, A., Eugenidis, N., 2009. Valeriana hepatotoxicity. *Sleep. Med.* 10 (8), 935.
- Vilar, J.H., García, M., Cabrera, P., 2000. Veno-occlusive liver disease induced by *Senecio vulgaris* toxicity. *Gastroenterol. Hepatol.* 23 (6), 285–286 [Article in Spanish].
- Vivekanandarajah, A., Ni, S., Waked, A., 2011. Acute hepatitis in a woman following excessive ingestion of an energy drink: a case report. *J. Med. Case Rep.* 22 (5), 227.
- Voican, C.S., Corruble, E., Naveau, S., Perlemuter, G., 2014. Antidepressant-induced liver injury: a review for clinicians. *Am. J. Psychiatry* 171 (4), 404–415.
- Vuppalanchi, R., Navarro, V., Vega, M., Bonkovsky, H.L., Seeff, L., Serrano, J., 2015. Drug-Induced Liver Injury Network (DILIN). Herbal dietary supplement associated hepatotoxicity: an upcoming workshop and need for research. *Gastroenterology* 148 (3), 480–482.
- Wainwright, J., Scotland, M.M., Candy, H.A., 1977. Toxicity of *Callilepis laureola*. *S. Afr. Med. J.* 52 (8), 313–315.
- Watson, A.R., Coovadia, H.M., Bhoola, K.D., 1979. The clinical syndrome of Impila (*Callilepis laureola*) poisoning in children. *S. Afr. Med. J.* 55 (8), 290–292.
- Weinstein, D.H., Twaddell, W.S., Raufman, J.P., Philosophe, B., Mindikoglu, A.L., 2012 Apr 27. SlimQuick™ - associated hepatotoxicity in a woman with alpha-1 antitrypsin heterozygosity. *World J. Hepatol.* 4 (4), 154–157.
- West, B.J., Jensen, C.J., Westendorf, J., White, L.D., 2007. A safety review of noni fruit juice. *J. Food Sci.* 71 (8), R100–R106.
- West, B.J., Jensen, C.J., Westendorf, J., 2006. Noni juice is not hepatotoxic. *World J. Gastroenterol.* 12 (22), 3616–3619.
- Weston, C.F., Cooper, B.T., Davies, J.D., Levine, D.F., 1987. Veno-occlusive disease of the liver secondary to ingestion of comfrey. *Br. Med. J. Clin. Res. Ed.* 295 (6591), 183.
- Whiting, P.W., Clouston, A., Kerlin, P., 2002. Black cohosh and other herbal remedies associated with acute hepatitis. *Med. J. Aust.* 177 (8), 440–443.
- Whitsett, M., Marzio, D.H., Rossi, S., 2014. SlimQuick™-Associated hepatotoxicity resulting in fulminant liver failure and orthotopic liver transplantation. *ACG Case Rep. J.* 1 (4), 220–222.
- Woolf, G.M., Petrovic, L.M., Rojter, S.E., Wainwright, S., et al., 1994. Acute hepatitis associated with the Chinese herbal product jin bu huan. *Ann. Intern. Med.* 121 (10), 729–735.
- World Health Organization (WHO). The use of the WHO-UMC system for standardized case causality assessment. <http://who-umc.org/Graphics/24734.pdf>. (accessed 08.09.15).
- Wysowski, D.K., Swartz, L., 2005. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. *Arch. Intern. Med.* 165 (12), 1363–1369.
- Yang, H.N., Kim, D.J., Kim, Y.M., Kim, B.H., Sohn, K.M., Choi, M.J., Choi, Y.H., 2010. Aloe-induced toxic hepatitis. *J. Korean Med. Sci.* 25, 492–495.
- Yang, L., Aronsohn, A., Hart, J., 2012. Jensen D. Herbal hepatotoxicity from Chinese skullcap: a case report. *World J. Hepatol.* 4 (7), 231–233.
- Yang, X.X., Hu, Z.P., Duan, W., Zhu, Y.Z., Zhou, S.F., 2006. Drug-herb interactions: eliminating toxicity with hard drug design. *Curr. Pharm. Des.* 12 (35), 4649–4664.
- Yeong, M.L., Swinburn, B., Kennedy, M., Nicholson, G., 1990. Hepatic veno-occlusive disease associated with comfrey ingestion. *J. Gastroenterol. Hepatol.* 5 (2), 211–214.
- Yuan, L., Kaplowitz, N., 2013. Mechanisms of drug-induced liver injury. *Clin. Liver Dis.* 17 (4), 507–518.
- Yu, K., Geng, X., Chen, M., Zhang, J., Wang, B., Ilic, K., Tong, W., 2014 Apr. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. *Drug Metab. Dispos.* 42 (4), 744–750.
- Yu, E.L., Sivagnanam, M., Ellis, L., et al., 2011. Acute hepatotoxicity after ingestion of *Morinda citrifolia* (noni berry) juice in a 14-year-old boy. *J. Pediatr. Gastroenterol. Nutr.* 52, 222–224.
- Yuce, B., Gulberg, V., Diebold, J., Gerbes, A.L., 2006. Hepatitis induced by Noni juice from *Morinda citrifolia*: a rare cause of hepatotoxicity or the tip of the iceberg? *Digestion* 73 (2–3), 167–170.
- Zheng, E.X., Navarro, V.J., 2015. Liver injury from herbal, dietary, and weight loss supplements: a review. *J. Clin. Transl. Hepatol.* 3 (2), 93–98.
- Zhou, Y., Yang, L., Liao, Z., He, X., Zhou, Y., Guo, H., 2013. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. *Eur. J. Gastroenterol. Hepatol.* 25 (7), 825–829.
- Zhou, S.F., Xue, C.C., Yu, X.Q., Li, C., Wang, G., 2007. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. *Ther. Drug Monit.* 29 (6), 687–710.